1
|
Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, Davis RJ, Flavell RA, Choi AM. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 2000; 6:422-8. [PMID: 10742149 DOI: 10.1038/74680] [Citation(s) in RCA: 1695] [Impact Index Per Article: 67.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The stress-inducible protein heme oxygenase-1 provides protection against oxidative stress. The anti-inflammatory properties of heme oxygenase-1 may serve as a basis for this cytoprotection. We demonstrate here that carbon monoxide, a by-product of heme catabolism by heme oxygenase, mediates potent anti-inflammatory effects. Both in vivo and in vitro, carbon monoxide at low concentrations differentially and selectively inhibited the expression of lipopolysaccharide-induced pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin-1beta, and macrophage inflammatory protein-1beta and increased the lipopolysaccharide-induced expression of the anti-inflammatory cytokine interleukin-10. Carbon monoxide mediated these anti-inflammatory effects not through a guanylyl cyclase-cGMP or nitric oxide pathway, but instead through a pathway involving the mitogen-activated protein kinases. These data indicate the possibility that carbon monoxide may have an important protective function in inflammatory disease states and thus has potential therapeutic uses.
Collapse
|
|
25 |
1695 |
2
|
Romanha AJ, Castro SLD, Soeiro MDNC, Lannes-Vieira J, Ribeiro I, Talvani A, Bourdin B, Blum B, Olivieri B, Zani C, Spadafora C, Chiari E, Chatelain E, Chaves G, Calzada JE, Bustamante JM, Freitas-Junior LH, Romero LI, Bahia MT, Lotrowska M, Soares M, Andrade SG, Armstrong T, Degrave W, Andrade ZDA. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz 2010; 105:233-8. [PMID: 20428688 DOI: 10.1590/s0074-02762010000200022] [Citation(s) in RCA: 280] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2009] [Accepted: 01/26/2010] [Indexed: 11/22/2022] Open
Abstract
Chagas disease, a neglected illness, affects nearly 12-14 million people in endemic areas of Latin America. Although the occurrence of acute cases sharply has declined due to Southern Cone Initiative efforts to control vector transmission, there still remain serious challenges, including the maintenance of sustainable public policies for Chagas disease control and the urgent need for better drugs to treat chagasic patients. Since the introduction of benznidazole and nifurtimox approximately 40 years ago, many natural and synthetic compounds have been assayed against Trypanosoma cruzi, yet only a few compounds have advanced to clinical trials. This reflects, at least in part, the lack of consensus regarding appropriate in vitro and in vivo screening protocols as well as the lack of biomarkers for treating parasitaemia. The development of more effective drugs requires (i) the identification and validation of parasite targets, (ii) compounds to be screened against the targets or the whole parasite and (iii) a panel of minimum standardised procedures to advance leading compounds to clinical trials. This third aim was the topic of the workshop entitled Experimental Models in Drug Screening and Development for Chagas Disease, held in Rio de Janeiro, Brazil, on the 25th and 26th of November 2008 by the Fiocruz Program for Research and Technological Development on Chagas Disease and Drugs for Neglected Diseases Initiative. During the meeting, the minimum steps, requirements and decision gates for the determination of the efficacy of novel drugs for T. cruzi control were evaluated by interdisciplinary experts and an in vitro and in vivo flowchart was designed to serve as a general and standardised protocol for screening potential drugs for the treatment of Chagas disease.
Collapse
|
Research Support, Non-U.S. Gov't |
15 |
280 |
3
|
Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH, Goldbach-Mansky R, Dean J, Athreya B, Reginato AJ, Henrickson M, Pons-Estel B, O'Shea JJ, Kastner DL. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001; 69:301-14. [PMID: 11443543 PMCID: PMC1235304 DOI: 10.1086/321976] [Citation(s) in RCA: 273] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2001] [Accepted: 06/06/2001] [Indexed: 11/03/2022] Open
Abstract
Mutations in the extracellular domain of the 55-kD tumor-necrosis factor (TNF) receptor (TNFRSF1A), a key regulator of inflammation, define a periodic-fever syndrome, TRAPS (TNF receptor-associated periodic syndrome [MIM 142680]), which is characterized by attacks of fever, sterile peritonitis, arthralgia, myalgia, skin rash, and/or conjunctivitis; some patients also develop systemic amyloidosis. Elsewhere we have described six disease-associated TNFRSF1A mutations, five of which disrupt extracellular cysteines involved in disulfide bonds; four other mutations have subsequently been reported. Among 150 additional patients with unexplained periodic fevers, we have identified four novel TNFRSF1A mutations (H22Y, C33G, S86P, and c.193-14 G-->A), one mutation (C30S) described by another group, and two substitutions (P46L and R92Q) present in approximately 1% of control chromosomes. The increased frequency of P46L and R92Q among patients with periodic fever, as well as functional studies of TNFRSF1A, argue that these are low-penetrance mutations rather than benign polymorphisms. The c.193-14 G-->A mutation creates a splice-acceptor site upstream of exon 3, resulting in a transcript encoding four additional extracellular amino acids. T50M and c.193-14 G-->A occur at CpG hotspots, and haplotype analysis is consistent with recurrent mutations at these sites. In contrast, although R92Q also arises at a CpG motif, we identified a common founder chromosome in unrelated individuals with this substitution. Genotype-phenotype studies identified, as carriers of cysteine mutations, 13 of 14 patients with TRAPS and amyloidosis and indicated a lower penetrance of TRAPS symptoms in individuals with noncysteine mutations. In two families with dominantly inherited disease and in 90 sporadic cases that presented with a compatible clinical history, we have not identified any TNFRSF1A mutation, despite comprehensive genomic sequencing of all of the exons, therefore suggesting further genetic heterogeneity of the periodic-fever syndromes.
Collapse
|
research-article |
24 |
273 |
4
|
Evans RA, Leavy OC, Richardson M, Elneima O, McAuley HJC, Shikotra A, Singapuri A, Sereno M, Saunders RM, Harris VC, Houchen-Wolloff L, Aul R, Beirne P, Bolton CE, Brown JS, Choudhury G, Diar-Bakerly N, Easom N, Echevarria C, Fuld J, Hart N, Hurst J, Jones MG, Parekh D, Pfeffer P, Rahman NM, Rowland-Jones SL, Shah AM, Wootton DG, Chalder T, Davies MJ, De Soyza A, Geddes JR, Greenhalf W, Greening NJ, Heaney LG, Heller S, Howard LS, Jacob J, Jenkins RG, Lord JM, Man WDC, McCann GP, Neubauer S, Openshaw PJM, Porter JC, Rowland MJ, Scott JT, Semple MG, Singh SJ, Thomas DC, Toshner M, Lewis KE, Thwaites RS, Briggs A, Docherty AB, Kerr S, Lone NI, Quint J, Sheikh A, Thorpe M, Zheng B, Chalmers JD, Ho LP, Horsley A, Marks M, Poinasamy K, Raman B, Harrison EM, Wain LV, Brightling CE, Abel K, Adamali H, Adeloye D, Adeyemi O, Adrego R, Aguilar Jimenez LA, Ahmad S, Ahmad Haider N, Ahmed R, Ahwireng N, Ainsworth M, Al-Sheklly B, Alamoudi A, Ali M, Aljaroof M, All AM, Allan L, Allen RJ, Allerton L, Allsop L, Almeida P, Altmann D, Alvarez Corral M, Amoils S, Anderson D, Antoniades C, Arbane G, Arias A, Armour C, et alEvans RA, Leavy OC, Richardson M, Elneima O, McAuley HJC, Shikotra A, Singapuri A, Sereno M, Saunders RM, Harris VC, Houchen-Wolloff L, Aul R, Beirne P, Bolton CE, Brown JS, Choudhury G, Diar-Bakerly N, Easom N, Echevarria C, Fuld J, Hart N, Hurst J, Jones MG, Parekh D, Pfeffer P, Rahman NM, Rowland-Jones SL, Shah AM, Wootton DG, Chalder T, Davies MJ, De Soyza A, Geddes JR, Greenhalf W, Greening NJ, Heaney LG, Heller S, Howard LS, Jacob J, Jenkins RG, Lord JM, Man WDC, McCann GP, Neubauer S, Openshaw PJM, Porter JC, Rowland MJ, Scott JT, Semple MG, Singh SJ, Thomas DC, Toshner M, Lewis KE, Thwaites RS, Briggs A, Docherty AB, Kerr S, Lone NI, Quint J, Sheikh A, Thorpe M, Zheng B, Chalmers JD, Ho LP, Horsley A, Marks M, Poinasamy K, Raman B, Harrison EM, Wain LV, Brightling CE, Abel K, Adamali H, Adeloye D, Adeyemi O, Adrego R, Aguilar Jimenez LA, Ahmad S, Ahmad Haider N, Ahmed R, Ahwireng N, Ainsworth M, Al-Sheklly B, Alamoudi A, Ali M, Aljaroof M, All AM, Allan L, Allen RJ, Allerton L, Allsop L, Almeida P, Altmann D, Alvarez Corral M, Amoils S, Anderson D, Antoniades C, Arbane G, Arias A, Armour C, Armstrong L, Armstrong N, Arnold D, Arnold H, Ashish A, Ashworth A, Ashworth M, Aslani S, Assefa-Kebede H, Atkin C, Atkin P, Aung H, Austin L, Avram C, Ayoub A, Babores M, Baggott R, Bagshaw J, Baguley D, Bailey L, Baillie JK, Bain S, Bakali M, Bakau M, Baldry E, Baldwin D, Ballard C, Banerjee A, Bang B, Barker RE, Barman L, Barratt S, Barrett F, Basire D, Basu N, Bates M, Bates A, Batterham R, Baxendale H, Bayes H, Beadsworth M, Beckett P, Beggs M, Begum M, Bell D, Bell R, Bennett K, Beranova E, Bermperi A, Berridge A, Berry C, Betts S, Bevan E, Bhui K, Bingham M, Birchall K, Bishop L, Bisnauthsing K, Blaikely J, Bloss A, Bolger A, Bonnington J, Botkai A, Bourne C, Bourne M, Bramham K, Brear L, Breen G, Breeze J, Bright E, Brill S, Brindle K, Broad L, Broadley A, Brookes C, Broome M, Brown A, Brown A, Brown J, Brown J, Brown M, Brown M, Brown V, Brugha T, Brunskill N, Buch M, Buckley P, Bularga A, Bullmore E, Burden L, Burdett T, Burn D, Burns G, Burns A, Busby J, Butcher R, Butt A, Byrne S, Cairns P, Calder PC, Calvelo E, Carborn H, Card B, Carr C, Carr L, Carson G, Carter P, Casey A, Cassar M, Cavanagh J, Chablani M, Chambers RC, Chan F, Channon KM, Chapman K, Charalambou A, Chaudhuri N, Checkley A, Chen J, Cheng Y, Chetham L, Childs C, Chilvers ER, Chinoy H, Chiribiri A, Chong-James K, Choudhury N, Chowienczyk P, Christie C, Chrystal M, Clark D, Clark C, Clarke J, Clohisey S, Coakley G, Coburn Z, Coetzee S, Cole J, Coleman C, Conneh F, Connell D, Connolly B, Connor L, Cook A, Cooper B, Cooper J, Cooper S, Copeland D, Cosier T, Coulding M, Coupland C, Cox E, Craig T, Crisp P, Cristiano D, Crooks MG, Cross A, Cruz I, Cullinan P, Cuthbertson D, Daines L, Dalton M, Daly P, Daniels A, Dark P, Dasgin J, David A, David C, Davies E, Davies F, Davies G, Davies GA, Davies K, Dawson J, Daynes E, Deakin B, Deans A, Deas C, Deery J, Defres S, Dell A, Dempsey K, Denneny E, Dennis J, Dewar A, Dharmagunawardena R, Dickens C, Dipper A, Diver S, Diwanji SN, Dixon M, Djukanovic R, Dobson H, Dobson SL, Donaldson A, Dong T, Dormand N, Dougherty A, Dowling R, Drain S, Draxlbauer K, Drury K, Dulawan P, Dunleavy A, Dunn S, Earley J, Edwards S, Edwardson C, El-Taweel H, Elliott A, Elliott K, Ellis Y, Elmer A, Evans D, Evans H, Evans J, Evans R, Evans RI, Evans T, Evenden C, Evison L, Fabbri L, Fairbairn S, Fairman A, Fallon K, Faluyi D, Favager C, Fayzan T, Featherstone J, Felton T, Finch J, Finney S, Finnigan J, Finnigan L, Fisher H, Fletcher S, Flockton R, Flynn M, Foot H, Foote D, Ford A, Forton D, Fraile E, Francis C, Francis R, Francis S, Frankel A, Fraser E, Free R, French N, Fu X, Furniss J, Garner L, Gautam N, George J, George P, Gibbons M, Gill M, Gilmour L, Gleeson F, Glossop J, Glover S, Goodman N, Goodwin C, Gooptu B, Gordon H, Gorsuch T, Greatorex M, Greenhaff PL, Greenhalgh A, Greenwood J, Gregory H, Gregory R, Grieve D, Griffin D, Griffiths L, Guerdette AM, Guillen Guio B, Gummadi M, Gupta A, Gurram S, Guthrie E, Guy Z, H Henson H, Hadley K, Haggar A, Hainey K, Hairsine B, Haldar P, Hall I, Hall L, Halling-Brown M, Hamil R, Hancock A, Hancock K, Hanley NA, Haq S, Hardwick HE, Hardy E, Hardy T, Hargadon B, Harrington K, Harris E, Harrison P, Harvey A, Harvey M, Harvie M, Haslam L, Havinden-Williams M, Hawkes J, Hawkings N, Haworth J, Hayday A, Haynes M, Hazeldine J, Hazelton T, Heeley C, Heeney JL, Heightman M, Henderson M, Hesselden L, Hewitt M, Highett V, Hillman T, Hiwot T, Hoare A, Hoare M, Hockridge J, Hogarth P, Holbourn A, Holden S, Holdsworth L, Holgate D, Holland M, Holloway L, Holmes K, Holmes M, Holroyd-Hind B, Holt L, Hormis A, Hosseini A, Hotopf M, Howard K, Howell A, Hufton E, Hughes AD, Hughes J, Hughes R, Humphries A, Huneke N, Hurditch E, Husain M, Hussell T, Hutchinson J, Ibrahim W, Ilyas F, Ingham J, Ingram L, Ionita D, Isaacs K, Ismail K, Jackson T, James WY, Jarman C, Jarrold I, Jarvis H, Jastrub R, Jayaraman B, Jezzard P, Jiwa K, Johnson C, Johnson S, Johnston D, Jolley CJ, Jones D, Jones G, Jones H, Jones H, Jones I, Jones L, Jones S, Jose S, Kabir T, Kaltsakas G, Kamwa V, Kanellakis N, Kaprowska S, Kausar Z, Keenan N, Kelly S, Kemp G, Kerslake H, Key AL, Khan F, Khunti K, Kilroy S, King B, King C, Kingham L, Kirk J, Kitterick P, Klenerman P, Knibbs L, Knight S, Knighton A, Kon O, Kon S, Kon SS, Koprowska S, Korszun A, Koychev I, Kurasz C, Kurupati P, Laing C, Lamlum H, Landers G, Langenberg C, Lasserson D, Lavelle-Langham L, Lawrie A, Lawson C, Lawson C, Layton A, Lea A, Lee D, Lee JH, Lee E, Leitch K, Lenagh R, Lewis D, Lewis J, Lewis V, Lewis-Burke N, Li X, Light T, Lightstone L, Lilaonitkul W, Lim L, Linford S, Lingford-Hughes A, Lipman M, Liyanage K, Lloyd A, Logan S, Lomas D, Loosley R, Lota H, Lovegrove W, Lucey A, Lukaschuk E, Lye A, Lynch C, MacDonald S, MacGowan G, Macharia I, Mackie J, Macliver L, Madathil S, Madzamba G, Magee N, Magtoto MM, Mairs N, Majeed N, Major E, Malein F, Malim M, Mallison G, Mandal S, Mangion K, Manisty C, Manley R, March K, Marciniak S, Marino P, Mariveles M, Marouzet E, Marsh S, Marshall B, Marshall M, Martin J, Martineau A, Martinez LM, Maskell N, Matila D, Matimba-Mupaya W, Matthews L, Mbuyisa A, McAdoo S, Weir McCall J, McAllister-Williams H, McArdle A, McArdle P, McAulay D, McCormick J, McCormick W, McCourt P, McGarvey L, McGee C, Mcgee K, McGinness J, McGlynn K, McGovern A, McGuinness H, McInnes IB, McIntosh J, McIvor E, McIvor K, McLeavey L, McMahon A, McMahon MJ, McMorrow L, Mcnally T, McNarry M, McNeill J, McQueen A, McShane H, Mears C, Megson C, Megson S, Mehta P, Meiring J, Melling L, Mencias M, Menzies D, Merida Morillas M, Michael A, Milligan L, Miller C, Mills C, Mills NL, Milner L, Misra S, Mitchell J, Mohamed A, Mohamed N, Mohammed S, Molyneaux PL, Monteiro W, Moriera S, Morley A, Morrison L, Morriss R, Morrow A, Moss AJ, Moss P, Motohashi K, Msimanga N, Mukaetova-Ladinska E, Munawar U, Murira J, Nanda U, Nassa H, Nasseri M, Neal A, Needham R, Neill P, Newell H, Newman T, Newton-Cox A, Nicholson T, Nicoll D, Nolan CM, Noonan MJ, Norman C, Novotny P, Nunag J, Nwafor L, Nwanguma U, Nyaboko J, O'Donnell K, O'Brien C, O'Brien L, O'Regan D, Odell N, Ogg G, Olaosebikan O, Oliver C, Omar Z, Orriss-Dib L, Osborne L, Osbourne R, Ostermann M, Overton C, Owen J, Oxton J, Pack J, Pacpaco E, Paddick S, Painter S, Pakzad A, Palmer S, Papineni P, Paques K, Paradowski K, Pareek M, Parfrey H, Pariante C, Parker S, Parkes M, Parmar J, Patale S, Patel B, Patel M, Patel S, Pattenadk D, Pavlides M, Payne S, Pearce L, Pearl JE, Peckham D, Pendlebury J, Peng Y, Pennington C, Peralta I, Perkins E, Peterkin Z, Peto T, Petousi N, Petrie J, Phipps J, Pimm J, Piper Hanley K, Pius R, Plant H, Plein S, Plekhanova T, Plowright M, Polgar O, Poll L, Porter J, Portukhay S, Powell N, Prabhu A, Pratt J, Price A, Price C, Price C, Price D, Price L, Price L, Prickett A, Propescu J, Pugmire S, Quaid S, Quigley J, Qureshi H, Qureshi IN, Radhakrishnan K, Ralser M, Ramos A, Ramos H, Rangeley J, Rangelov B, Ratcliffe L, Ravencroft P, Reddington A, Reddy R, Redfearn H, Redwood D, Reed A, Rees M, Rees T, Regan K, Reynolds W, Ribeiro C, Richards A, Richardson E, Rivera-Ortega P, Roberts K, Robertson E, Robinson E, Robinson L, Roche L, Roddis C, Rodger J, Ross A, Ross G, Rossdale J, Rostron A, Rowe A, Rowland A, Rowland J, Roy K, Roy M, Rudan I, Russell R, Russell E, Saalmink G, Sabit R, Sage EK, Samakomva T, Samani N, Sampson C, Samuel K, Samuel R, Sanderson A, Sapey E, Saralaya D, Sargant J, Sarginson C, Sass T, Sattar N, Saunders K, Saunders P, Saunders LC, Savill H, Saxon W, Sayer A, Schronce J, Schwaeble W, Scott K, Selby N, Sewell TA, Shah K, Shah P, Shankar-Hari M, Sharma M, Sharpe C, Sharpe M, Shashaa S, Shaw A, Shaw K, Shaw V, Shelton S, Shenton L, Shevket K, Short J, Siddique S, Siddiqui S, Sidebottom J, Sigfrid L, Simons G, Simpson J, Simpson N, Singh C, Singh S, Sissons D, Skeemer J, Slack K, Smith A, Smith D, Smith S, Smith J, Smith L, Soares M, Solano TS, Solly R, Solstice AR, Soulsby T, Southern D, Sowter D, Spears M, Spencer LG, Speranza F, Stadon L, Stanel S, Steele N, Steiner M, Stensel D, Stephens G, Stephenson L, Stern M, Stewart I, Stimpson R, Stockdale S, Stockley J, Stoker W, Stone R, Storrar W, Storrie A, Storton K, Stringer E, Strong-Sheldrake S, Stroud N, Subbe C, Sudlow CL, Suleiman Z, Summers C, Summersgill C, Sutherland D, Sykes DL, Sykes R, Talbot N, Tan AL, Tarusan L, Tavoukjian V, Taylor A, Taylor C, Taylor J, Te A, Tedd H, Tee CJ, Teixeira J, Tench H, Terry S, Thackray-Nocera S, Thaivalappil F, Thamu B, Thickett D, Thomas C, Thomas S, Thomas AK, Thomas-Woods T, Thompson T, Thompson AAR, Thornton T, Tilley J, Tinker N, Tiongson GF, Tobin M, Tomlinson J, Tong C, Touyz R, Tripp KA, Tunnicliffe E, Turnbull A, Turner E, Turner S, Turner V, Turner K, Turney S, Turtle L, Turton H, Ugoji J, Ugwuoke R, Upthegrove R, Valabhji J, Ventura M, Vere J, Vickers C, Vinson B, Wade E, Wade P, Wainwright T, Wajero LO, Walder S, Walker S, Walker S, Wall E, Wallis T, Walmsley S, Walsh JA, Walsh S, Warburton L, Ward TJC, Warwick K, Wassall H, Waterson S, Watson E, Watson L, Watson J, Welch C, Welch H, Welsh B, Wessely S, West S, Weston H, Wheeler H, White S, Whitehead V, Whitney J, Whittaker S, Whittam B, Whitworth V, Wight A, Wild J, Wilkins M, Wilkinson D, Williams N, Williams N, Williams J, Williams-Howard SA, Willicombe M, Willis G, Willoughby J, Wilson A, Wilson D, Wilson I, Window N, Witham M, Wolf-Roberts R, Wood C, Woodhead F, Woods J, Wormleighton J, Worsley J, Wraith D, Wrey Brown C, Wright C, Wright L, Wright S, Wyles J, Wynter I, Xu M, Yasmin N, Yasmin S, Yates T, Yip KP, Young B, Young S, Young A, Yousuf AJ, Zawia A, Zeidan L, Zhao B, Zongo O. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. THE LANCET. RESPIRATORY MEDICINE 2022; 10:761-775. [PMID: 35472304 PMCID: PMC9034855 DOI: 10.1016/s2213-2600(22)00127-8] [Show More Authors] [Citation(s) in RCA: 209] [Impact Index Per Article: 69.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Revised: 03/23/2022] [Accepted: 03/31/2022] [Indexed: 11/25/2022]
Abstract
BACKGROUND No effective pharmacological or non-pharmacological interventions exist for patients with long COVID. We aimed to describe recovery 1 year after hospital discharge for COVID-19, identify factors associated with patient-perceived recovery, and identify potential therapeutic targets by describing the underlying inflammatory profiles of the previously described recovery clusters at 5 months after hospital discharge. METHODS The Post-hospitalisation COVID-19 study (PHOSP-COVID) is a prospective, longitudinal cohort study recruiting adults (aged ≥18 years) discharged from hospital with COVID-19 across the UK. Recovery was assessed using patient-reported outcome measures, physical performance, and organ function at 5 months and 1 year after hospital discharge, and stratified by both patient-perceived recovery and recovery cluster. Hierarchical logistic regression modelling was performed for patient-perceived recovery at 1 year. Cluster analysis was done using the clustering large applications k-medoids approach using clinical outcomes at 5 months. Inflammatory protein profiling was analysed from plasma at the 5-month visit. This study is registered on the ISRCTN Registry, ISRCTN10980107, and recruitment is ongoing. FINDINGS 2320 participants discharged from hospital between March 7, 2020, and April 18, 2021, were assessed at 5 months after discharge and 807 (32·7%) participants completed both the 5-month and 1-year visits. 279 (35·6%) of these 807 patients were women and 505 (64·4%) were men, with a mean age of 58·7 (SD 12·5) years, and 224 (27·8%) had received invasive mechanical ventilation (WHO class 7-9). The proportion of patients reporting full recovery was unchanged between 5 months (501 [25·5%] of 1965) and 1 year (232 [28·9%] of 804). Factors associated with being less likely to report full recovery at 1 year were female sex (odds ratio 0·68 [95% CI 0·46-0·99]), obesity (0·50 [0·34-0·74]) and invasive mechanical ventilation (0·42 [0·23-0·76]). Cluster analysis (n=1636) corroborated the previously reported four clusters: very severe, severe, moderate with cognitive impairment, and mild, relating to the severity of physical health, mental health, and cognitive impairment at 5 months. We found increased inflammatory mediators of tissue damage and repair in both the very severe and the moderate with cognitive impairment clusters compared with the mild cluster, including IL-6 concentration, which was increased in both comparisons (n=626 participants). We found a substantial deficit in median EQ-5D-5L utility index from before COVID-19 (retrospective assessment; 0·88 [IQR 0·74-1·00]), at 5 months (0·74 [0·64-0·88]) to 1 year (0·75 [0·62-0·88]), with minimal improvements across all outcome measures at 1 year after discharge in the whole cohort and within each of the four clusters. INTERPRETATION The sequelae of a hospital admission with COVID-19 were substantial 1 year after discharge across a range of health domains, with the minority in our cohort feeling fully recovered. Patient-perceived health-related quality of life was reduced at 1 year compared with before hospital admission. Systematic inflammation and obesity are potential treatable traits that warrant further investigation in clinical trials. FUNDING UK Research and Innovation and National Institute for Health Research.
Collapse
|
Observational Study |
3 |
209 |
5
|
Brostjan C, Anrather J, Csizmadia V, Stroka D, Soares M, Bach FH, Winkler H. Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis. J Biol Chem 1996; 271:19612-6. [PMID: 8702657 DOI: 10.1074/jbc.271.32.19612] [Citation(s) in RCA: 169] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Repression of NFkappaB-dependent gene expression is one of the major elements of immunosuppression by glucocorticoids. Protein-protein interactions between the glucocorticoid receptor and NFkappaB have been characterized and shown to be a possible mechanism of mutual inhibition of transactivation properties. More recently, glucocorticoid-mediated induction of IkappaBalpha, an inhibitor of NFkappaB, has been described in monocytes and lymphocytes; an increase in IkappaBalpha mRNA and protein resulted in inactivation and cytosolic retention of NFkappaB. Thus, rather than the physical interaction between the glucocorticoid receptor and NFkappaB, the up-regulation of IkappaBalpha was presented as the key element in immunosuppression by glucocorticoids. In contrast, we show that the IkappaBalpha pathway is not involved in glucocorticoid-mediated inhibition of NFkappaB activity in endothelial cells. Although transcriptional activation by NFkappaB was significantly reduced in the presence of glucocorticoids, we did not detect induction of IkappaBalpha protein that could prevent nuclear translocation of NFkappaB upon stimulation with lipopolysaccharide or tumor necrosis factor alpha. Furthermore, treatment with glucocorticoids did not seem to affect the transcription rate or mRNA stability of IkappaBalpha. We therefore conclude that, although induction of IkappaBalpha expression by glucocorticoids seems to be of importance in monocytes and lymphocytes, it cannot explain inhibition of NFkappaB-dependent gene expression in endothelial cells. Our results emphasize the relevance of physical interaction between the glucocorticoid receptor and NFkappaB in endothelial cells and thus in suppression of inflammation by glucocorticoids.
Collapse
|
|
29 |
169 |
6
|
Rhodes A, Moreno RP, Azoulay E, Capuzzo M, Chiche JD, Eddleston J, Endacott R, Ferdinande P, Flaatten H, Guidet B, Kuhlen R, León-Gil C, Martin Delgado MC, Metnitz PG, Soares M, Sprung CL, Timsit JF, Valentin A. Prospectively defined indicators to improve the safety and quality of care for critically ill patients: a report from the Task Force on Safety and Quality of the European Society of Intensive Care Medicine (ESICM). Intensive Care Med 2012; 38:598-605. [DOI: 10.1007/s00134-011-2462-3] [Citation(s) in RCA: 162] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2011] [Accepted: 12/28/2011] [Indexed: 10/14/2022]
|
|
13 |
162 |
7
|
Flaatten H, de Lange DW, Artigas A, Bin D, Moreno R, Christensen S, Joynt GM, Bagshaw SM, Sprung CL, Benoit D, Soares M, Guidet B. The status of intensive care medicine research and a future agenda for very old patients in the ICU. Intensive Care Med 2017; 43:1319-1328. [PMID: 28238055 DOI: 10.1007/s00134-017-4718-z] [Citation(s) in RCA: 110] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2016] [Accepted: 02/08/2017] [Indexed: 02/01/2023]
Abstract
The "very old intensive care patients" (abbreviated to VOPs; greater than 80 years old) are probably the fastest expanding subgroup of all intensive care unit (ICU) patients. Up until recently most ICU physicians have been reluctant to admit these VOPs. The general consensus was that there was little survival to gain and the incremental life expectancy of ICU admission was considered too small. Several publications have questioned this belief, but others have confirmed the poor long-term mortality rates in VOPs. More appropriate triage (resource limitation enforced decisions), admission decisions based on shared decision-making and improved prediction models are also needed for this particular patient group. Here, an expert panel proposes a research agenda for VOPs for the coming years.
Collapse
|
Review |
8 |
110 |
8
|
Morandi A, Pandharipande P, Trabucchi M, Rozzini R, Mistraletti G, Trompeo AC, Gregoretti C, Gattinoni L, Ranieri MV, Brochard L, Annane D, Putensen C, Guenther U, Fuentes P, Tobar E, Anzueto AR, Esteban A, Skrobik Y, Salluh JIF, Soares M, Granja C, Stubhaug A, de Rooij SE, Ely EW. Understanding international differences in terminology for delirium and other types of acute brain dysfunction in critically ill patients. Intensive Care Med 2008; 34:1907-15. [PMID: 18563387 DOI: 10.1007/s00134-008-1177-6] [Citation(s) in RCA: 100] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2008] [Accepted: 05/21/2008] [Indexed: 11/29/2022]
Abstract
BACKGROUND Delirium (acute brain dysfunction) is a potentially life threatening disturbance in brain function that frequently occurs in critically ill patients. While this area of brain dysfunction in critical care is rapidly advancing, striking limitations in use of terminology related to delirium internationally are hindering cross-talk and collaborative research. In the English literature, synonyms of delirium such as the Intensive Care Unit syndrome, acute brain dysfunction, acute brain failure, psychosis, confusion, and encephalopathy are widely used. This often leads to scientific "confusion" regarding published data and methodology within studies, which is further exacerbated by organizational, cultural and language barriers. OBJECTIVE We undertook this multinational effort to identify conflicts in terminology and phenomenology of delirium to facilitate communication across medical disciplines and languages. METHODS The evaluation of the terminology used for acute brain dysfunction was determined conducting communications with 24 authors from academic communities throughout countries/regions that speak the 13 variants of the Romanic languages included into this manuscript. RESULTS In the 13 languages utilizing Romanic characters, included in this report, we identified the following terms used to define major types of acute brain dysfunction: coma, delirium, delirio, delirium tremens, délire, confusion mentale, delir, delier, Durchgangs-Syndrom, acute verwardheid, intensiv-psykose, IVA-psykos, IVA-syndrom, akutt konfusion/forvirring. Interestingly two terms are very consistent: 100 % of the selected languages use the term coma or koma to describe patients unresponsive to verbal and/or physical stimuli, and 100% use delirium tremens to define delirium due to alcohol withdrawal. Conversely, only 54% use the term delirium to indicate the disorder as defined by the DSM-IV as an acute change in mental status, inattention, disorganized thinking and altered level of consciousness. CONCLUSIONS Attempts towards standardization in terminology, or at least awareness of differences across languages and specialties, will help cross-talk among clinicians and researchers.
Collapse
|
Journal Article |
17 |
100 |
9
|
Bach FH, Ferran C, Soares M, Wrighton CJ, Anrather J, Winkler H, Robson SC, Hancock WW. Modification of vascular responses in xenotransplantation: inflammation and apoptosis. Nat Med 1997; 3:944-8. [PMID: 9288711 DOI: 10.1038/nm0997-944] [Citation(s) in RCA: 94] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
Review |
28 |
94 |
10
|
Marra M, Hillier L, Kucaba T, Allen M, Barstead R, Beck C, Blistain A, Bonaldo M, Bowers Y, Bowles L, Cardenas M, Chamberlain A, Chappell J, Clifton S, Favello A, Geisel S, Gibbons M, Harvey N, Hill F, Jackson Y, Kohn S, Lennon G, Mardis E, Martin J, Mila L, McCann R, Morales R, Pape D, Person B, Prange C, Ritter E, Soares M, Schurk R, Shin T, Steptoe M, Swaller T, Theising B, Underwood K, Wylie T, Yount T, Wilson R, Waterston R. An encyclopedia of mouse genes. Nat Genet 1999; 21:191-4. [PMID: 9988271 DOI: 10.1038/5976] [Citation(s) in RCA: 91] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The laboratory mouse is the premier model system for studies of mammalian development due to the powerful classical genetic analysis possible (see also the Jackson Laboratory web site, http://www.jax.org/) and the ever-expanding collection of molecular tools. To enhance the utility of the mouse system, we initiated a program to generate a large database of expressed sequence tags (ESTs) that can provide rapid access to genes. Of particular significance was the possibility that cDNA libraries could be prepared from very early stages of development, a situation unrealized in human EST projects. We report here the development of a comprehensive database of ESTs for the mouse. The project, initiated in March 1996, has focused on 5' end sequences from directionally cloned, oligo-dT primed cDNA libraries. As of 23 October 1998, 352,040 sequences had been generated, annotated and deposited in dbEST, where they comprised 93% of the total ESTs available for mouse. EST data are versatile and have been applied to gene identification, comparative sequence analysis, comparative gene mapping and candidate disease gene identification, genome sequence annotation, microarray development and the development of gene-based map resources.
Collapse
|
|
26 |
91 |
11
|
Siegel JB, Grey ST, Lesnikoski BA, Kopp CW, Soares M, Schulte am Esch J, Bach FH, Robson SC. Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997; 64:888-96. [PMID: 9326416 DOI: 10.1097/00007890-199709270-00017] [Citation(s) in RCA: 89] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND Delayed xenograft rejection is characterized by platelet activation and fibrin deposition and is thought to occur independently of complement activation. We have therefore investigated the potential for xenogeneic endothelial cells (EC) to regulate the conversion of prothrombin to thrombin, a central component of the final common pathway of coagulation and an important platelet agonist. METHODS AND RESULTS Quiescent porcine aortic EC (PAEC) were found to convert high levels of human prothrombin to thrombin (0.234+/-0.019 IU/ml) when compared with human aortic EC (0.017+/-0 IU/ml, 30-min time point, chromogenic assay; P<0.001). PAEC activation by human complement resulted in comparable levels of thrombin generation. Prothrombin conversion by PAEC as determined by generation of F1+2 (1.909+/-0.119 nmol/L) and formation of thrombin-antithrombin III complexes (125.611+/-6.373 microg/L) was significantly greater than the matched human aortic EC values (F1+2: 1.539+/-0.03 nmol/L, P<0.001; thrombin-antithrombin III: 1.833+/-0.104 microg/L, P<0.001). Sequential analysis of prothrombin activation by PAEC indicated generation of the intermediate meizothrombin followed by autolytically accelerated thrombin formation. Subsequent experiments established important cross-species' incompatibilities with respect to porcine thrombomodulin interaction with human thrombin and protein C in that PAEC had a reduced capacity to generate activated human protein C in vitro. CONCLUSION These observations indicate a potentially important molecular barrier involving blood coagulation that may impact on the planned clinical application of porcine transgenic organs.
Collapse
|
Comparative Study |
28 |
89 |
12
|
Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, Soares M, Spackman E, Youn J. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. Health Technol Assess 2013. [PMID: 23177626 DOI: 10.3310/hta16460] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND The general issue of balancing the value of evidence about the performance of a technology and the value of access to a technology can be seen as central to a number of policy questions. Establishing the key principles of what assessments are needed, as well as how they should be made, will enable them to be addressed in an explicit and transparent manner. OBJECTIVES The aims of this research are to (1) establish the key principles of what assessments are needed to inform an 'only in research' (OIR) or 'approval with research' (AWR) recommendation, (2) evaluate previous National Institute for Health and Clinical Evidence (NICE) guidance in which OIR or AWR recommendations were made or considered and (3) evaluate a range of alternative options to establish criteria, additional information and/or analysis that could be made available to inform the assessments needed. DATA SOURCES All NICE draft and final guidance up to January 2010 was considered in the review of NICE technology appraisal guidance. Four case studies were used to evaluate the range of options of what information and analysis could be made available to inform the assessment required. These were based on a reanalysis of existing health technology appraisals for NICE or the Health Technology Assessment programme. REVIEW METHODS A critical review of policies, practice and literature was undertaken using traditional systematic searching based on initial search terms informed by key publications. An iterative approach was adopted using 'pearl growing' evaluated through capture-recapture methods. In addition, grey literature, policy documents and other sources, such as special interest groups and the expertise of the Advisory Group for the project, were used to contribute to this process. RESULTS A series of recommendations, or options, for NICE to consider were developed with the involvement of key stakeholders. These establish the key principles and associated criteria that might guide OIR and AWR recommendations and identify what, if any, additional information or analysis might be included in the technology appraisal process, including how such recommendations might be more likely to be implemented through publically funded and sponsored research. To meet these aims the research is broadly structured as follows. A critical review of policy, practice and literature in this area informs the development of a coherent conceptual framework to establish the key principles and the sequence of assessment and judgements required. This sequence of assessment and judgement is represented as an algorithm, which can also be summarised as a simple set of explicit criteria or a 7-point checklist of assessments. A review of previous NICE guidance in which OIR or AWR recommendations were either made or considered was undertaken to examine the extent to which the key principles are evident. The application of the checklist of assessment to a series of four case studies informs considerations of whether or not such assessments can be made based on existing information and analysis in current NICE appraisal and in what circumstances could additional information and/or analysis be useful. Finally, some of the implications that this more explicit assessment of OIR and AWR might have for policy (e.g. NICE guidance and drug pricing), the process of appraisal (e.g. greater involvement of research commissioners) and methods of appraisal (e.g. should additional information, evidence and analysis be required) are drawn together. At each stage this research has been informed by a diverse and international Advisory Group and the feedback from participants at two workshops involving a wide range of key stakeholders, which included members of NICE and its Advisory Committees (including lay members and other NICE programmes), patient advocates, manufacturers, and research and NHS commissioners, as well as relevant academics. LIMITATIONS Further research is required to establish how these considerations could be integrated within a practical value-based pricing scheme. In addition, irrecoverable opportunity costs are commonly associated with many health technologies that offer future benefits following treatment. The significance of these types of irrecoverable costs is not widely recognised and further research to demonstrate their potential impact more generally is needed. CONCLUSIONS The categories of guidance available to NICE have a wider application than is reflected in the review of previous guidance. Importantly, determining which category of guidance will be appropriate depends only partly on an assessment of expected cost-effectiveness. As well as AWR for technologies expected to be cost-effective and OIR for those not expected to be cost-effective, there are other important circumstances when OIR should be considered. In particular, for technologies expected to be cost-effective, OIR rather than approve may be appropriate when research is not possible with approval and OIR or even reject, rather than AWR or approve, may be appropriate even if research is possible with approval when there are significant irrecoverable costs. FUNDING The National Institute for Health Research Health Technology Assessment programme.
Collapse
|
Research Support, Non-U.S. Gov't |
12 |
71 |
13
|
Soares M, Toffart AC, Timsit JF, Burghi G, Irrazábal C, Pattison N, Tobar E, Almeida BFC, Silva UVA, Azevedo LCP, Rabbat A, Lamer C, Parrot A, Souza-Dantas VC, Wallet F, Blot F, Bourdin G, Piras C, Delemazure J, Durand M, Tejera D, Salluh JIF, Azoulay E. Intensive care in patients with lung cancer: a multinational study. Ann Oncol 2014; 25:1829-1835. [PMID: 24950981 DOI: 10.1093/annonc/mdu234] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Detailed information about lung cancer patients requiring admission to intensive care units (ICUs) is mostly restricted to single-center studies. Our aim was to evaluate the clinical characteristics and outcomes of lung cancer patients admitted to ICUs. PATIENTS AND METHODS Prospective multicenter study in 449 patients with lung cancer (small cell, n = 55; non-small cell, n = 394) admitted to 22 ICUs in six countries in Europe and South America during 2011. Multivariate Cox proportional hazards frailty models were built to identify characteristics associated with 30-day and 6-month mortality. RESULTS Most of the patients (71%) had newly diagnosed cancer. Cancer-related complications occurred in 56% of patients; the most common was tumoral airway involvement (26%). Ventilatory support was required in 53% of patients. Overall hospital, 30-day, and 6-month mortality rates were 39%, 41%, and 55%, respectively. After adjustment for type of admission and early treatment-limitation decisions, determinants of mortality were organ dysfunction severity, poor performance status (PS), recurrent/progressive cancer, and cancer-related complications. Mortality rates were far lower in the patient subset with nonrecurrent/progressive cancer and a good PS, even those with sepsis, multiple organ dysfunctions, and need for ventilatory support. Mortality was also lower in high-volume centers. Poor PS predicted failure to receive the initially planned cancer treatment after hospital discharge. CONCLUSIONS ICU admission was associated with meaningful survival in lung cancer patients with good PS and non-recurrent/progressive disease. Conversely, mortality rates were very high in patients not fit for anticancer treatment and poor PS. In this subgroup, palliative care may be the best option.
Collapse
|
Multicenter Study |
11 |
66 |
14
|
Lanzaro GC, Lopes AH, Ribeiro JM, Shoemaker CB, Warburg A, Soares M, Titus RG. Variation in the salivary peptide, maxadilan, from species in the Lutzomyia longipalpis complex. INSECT MOLECULAR BIOLOGY 1999; 8:267-275. [PMID: 10380110 DOI: 10.1046/j.1365-2583.1999.820267.x] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Maxadilan is an approximately 7kDa peptide that occurs in the saliva of the sand fly Lutzomyia longipalpis. This peptide is a potent vasodilator and may also have immunomodulatory effects related to the pathogenesis of leishmanial infections. Variation in the primary DNA and inferred amino acid sequence of maxadilan is reported. Differences were found within and among natural field populations as well as among sibling species. Extensive amino acid sequence differentiation, up to 23%, was observed among maxadilan from different populations. This is a remarkable degree of polymorphism considering the small size of this peptide. The vasodilatory activity of maxadilan was equivalent among recombinant maxadilan variants. All maxadilan variants induce interleukin-6. Predicted secondary structure and hydrophobicity plots suggest that these characteristics are conserved among variant peptides. However, profiles based on the antigenic index do differ among peptides.
Collapse
|
|
26 |
60 |
15
|
Rodgers M, Soares M, Epstein D, Yang H, Fox D, Eastwood A. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer. Health Technol Assess 2011. [DOI: 10.3310/hta15suppl1-01] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
This paper presents a summary of the evidence review group (ERG) report into the use of bevacizumab (Avastin®, Roche) in combination with a taxane for the treatment of untreated metastatic breast cancer (mBC). The main clinical effectiveness data were derived from a single, open-label randomised controlled trial (RCT) (E2100) that evaluated the addition of bevacizumab to weekly (q.w.) paclitaxel in patients with human epidermal growth factor receptor 2-negative mBC who had not previously received chemotherapy for advanced disease. This trial reported statistically significant increases in median progression-free survival (PFS) for the addition of bevacizumab (5.8–11.3 months). Median overall survival was not significantly different between the two groups; whether this is a true null finding or due to crossover between treatment arms cannot be established, as relevant data were not collected. The manufacturer reported that the addition of bevacizumab to paclitaxel q.w. therapy was associated with a significant improvement in quality of life, as measured by FACT-B (functional assessment of cancer therapy for breast cancer) scores. However, the ERG noted that these results were based on extreme imputed values, the removal of which led to non-significant differences in quality of life. The manufacturer conducted an indirect comparison. However, owing to methodological limitations and concerns about the validity and exchangeability of the included trials, the ERG did not consider the findings to be reliable. One additional relevant RCT [AVADO (Avastin and Docetaxel); BO17708] evaluating the addition of bevacizumab to docetaxel was excluded from the manufacturer’s submission. This was summarised by the ERG. In terms of response rate and PFS, AVADO reported a markedly smaller benefit of adding bevacizumab to docetaxel than that reported for adding bevacizumab to q.w. paclitaxel in E2100. AVADO also reported no statistically significant effect of combination therapy versus docetaxel in terms of overall survival. The manufacturer developed a de novo economic model that considered patients with the same baseline characteristics as women in the E2100 trial. The model assessed BEV + PAC – bevacizumab 10 mg/kg every 2 weeks in combination with paclitaxel 90 mg/m2 weekly for 3 weeks followed by 1 week of rest; PAC q.w. – paclitaxel (monotherapy) 90 mg/m2 weekly for 3 weeks followed by 1 week of rest; DOC – docetaxel (monotherapy) 75 mg/m2 on day 1 every 21 days (considered current UK NHS clinical practice in the submission); and GEM + PAC – gemcitabine 1250 mg/m2 on days 1 and 8 plus paclitaxel 175 mg/m2 on day 1 every 21 days. Pairwise comparisons were made between BEV + PAC and PAC (using the E2100 trial), BEV + PAC and DOC, and BEV + PAC and GEM + PAC. Based on NHS list prices, the manufacturer’s model estimated incremental cost-effectiveness ratios (ICERs) for BEV + PAC of £117,803, £115,059 and £105,777 per QALY gained, relative to PAC, DOC and GEM + PAC regimens, respectively. If the NHS Purchasing and Supply Agency prices for PAC with a 10-g cap on the cost per patient of BEV were used instead, the ICERs for BEV + PAC were estimated at £77,314, £57,753 and £60,101 per QALY, respectively. The submission suggested that the regimen of BEV + DOC is not cost-effective because it is considered less effective and more costly than BEV + PAC. Analysis by the ERG suggested that alternative assumptions can increase the ICERs further and, based on current prices, no plausible changes to the model assumptions will bring the ICERs for BEV + PAC lower.
Collapse
|
|
14 |
56 |
16
|
Aaij R, Abellán Beteta C, Ackernley T, Adeva B, Adinolfi M, Afsharnia H, Aidala C, Aiola S, Ajaltouni Z, Akar S, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Aliouche Z, Alkhazov G, Alvarez Cartelle P, Amato S, Amhis Y, An L, Anderlini L, Andreianov A, Andreotti M, Archilli F, Artamonov A, Artuso M, Arzymatov K, Aslanides E, Atzeni M, Audurier B, Bachmann S, Bachmayer M, Back J, Baker S, Baladron Rodriguez P, Balagura V, Baldini W, Baptista Leite J, Barlow R, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Basels J, Bassi G, Batsukh B, Battig A, Bay A, Becker M, Bedeschi F, Bediaga I, Beiter A, Belavin V, Belin S, Bellee V, Belous K, Belov I, Belyaev I, Bencivenni G, Ben-Haim E, Berezhnoy A, Bernet R, Berninghoff D, Bernstein H, Bertella C, Bertholet E, Bertolin A, Betancourt C, Betti F, Bettler M, Bezshyiko I, Bhasin S, Bhom J, Bian L, Bieker M, Bifani S, Billoir P, Birch M, Bishop F, Bizzeti A, Bjørn M, Blago M, Blake T, Blanc F, Blusk S, Bobulska D, Boelhauve J, Boente Garcia O, Boettcher T, Boldyrev A, Bondar A, Bondar N, Borghi S, Borisyak M, Borsato M, Borsuk J, Bouchiba S, Bowcock T, Boyer A, Bozzi C, et alAaij R, Abellán Beteta C, Ackernley T, Adeva B, Adinolfi M, Afsharnia H, Aidala C, Aiola S, Ajaltouni Z, Akar S, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Aliouche Z, Alkhazov G, Alvarez Cartelle P, Amato S, Amhis Y, An L, Anderlini L, Andreianov A, Andreotti M, Archilli F, Artamonov A, Artuso M, Arzymatov K, Aslanides E, Atzeni M, Audurier B, Bachmann S, Bachmayer M, Back J, Baker S, Baladron Rodriguez P, Balagura V, Baldini W, Baptista Leite J, Barlow R, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Basels J, Bassi G, Batsukh B, Battig A, Bay A, Becker M, Bedeschi F, Bediaga I, Beiter A, Belavin V, Belin S, Bellee V, Belous K, Belov I, Belyaev I, Bencivenni G, Ben-Haim E, Berezhnoy A, Bernet R, Berninghoff D, Bernstein H, Bertella C, Bertholet E, Bertolin A, Betancourt C, Betti F, Bettler M, Bezshyiko I, Bhasin S, Bhom J, Bian L, Bieker M, Bifani S, Billoir P, Birch M, Bishop F, Bizzeti A, Bjørn M, Blago M, Blake T, Blanc F, Blusk S, Bobulska D, Boelhauve J, Boente Garcia O, Boettcher T, Boldyrev A, Bondar A, Bondar N, Borghi S, Borisyak M, Borsato M, Borsuk J, Bouchiba S, Bowcock T, Boyer A, Bozzi C, Bradley M, Braun S, Brea Rodriguez A, Brodski M, Brodzicka J, Brossa Gonzalo A, Brundu D, Buonaura A, Burr C, Bursche A, Butkevich A, Butter J, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Calefice L, Calero Diaz L, Cali S, Calladine R, Calvi M, Calvo Gomez M, Camargo Magalhaes P, Camboni A, Campana P, Campora Perez D, Campoverde Quezada A, Capelli S, Capriotti L, Carbone A, Carboni G, Cardinale R, Cardini A, Carli I, Carniti P, Carvalho Akiba K, Casais Vidal A, Casse G, Cattaneo M, Cavallero G, Celani S, Cerasoli J, Chadwick A, Chapman M, Charles M, Charpentier P, Chatzikonstantinidis G, Chavez Barajas C, Chefdeville M, Chen C, Chen S, Chernov A, Chitic SG, Chobanova V, Cholak S, Chrzaszcz M, Chubykin A, Chulikov V, Ciambrone P, Cicala M, Cid Vidal X, Ciezarek G, Clarke P, Clemencic M, Cliff H, Closier J, Cobbledick J, Coco V, Coelho J, Cogan J, Cogneras E, Cojocariu L, Collins P, Colombo T, Congedo L, Contu A, Cooke N, Coombs G, Corti G, Costa Sobral C, Couturier B, Craik D, Crkovská J, Cruz Torres M, Currie R, Da Silva C, Dall’Occo E, Dalseno J, D’Ambrosio C, Danilina A, d’Argent P, Davis A, De Aguiar Francisco O, De Bruyn K, De Capua S, De Cian M, De Miranda J, De Paula L, De Serio M, De Simone D, De Simone P, de Vries J, Dean C, Dean W, Decamp D, Del Buono L, Delaney B, Dembinski HP, Dendek A, Denysenko V, Derkach D, Deschamps O, Desse F, Dettori F, Dey B, Di Nezza P, Didenko S, Dieste Maronas L, Dijkstra H, Dobishuk V, Donohoe A, Dordei F, dos Reis A, Douglas L, Dovbnya A, Downes A, Dreimanis K, Dudek M, Dufour L, Duk V, Durante P, Durham J, Dutta D, Dziewiecki M, Dziurda A, Dzyuba A, Easo S, Egede U, Egorychev V, Eidelman S, Eisenhardt S, Ek-In S, Eklund L, Ely S, Ene A, Epple E, Escher S, Eschle J, Esen S, Evans T, Falabella A, Fan J, Fan Y, Fang B, Farley N, Farry S, Fazzini D, Fedin P, Féo M, Fernandez Declara P, Fernandez Prieto A, Fernandez-tenllado Arribas J, Ferrari F, Ferreira Lopes L, Ferreira Rodrigues F, Ferreres Sole S, Ferrillo M, Ferro-Luzzi M, Filippov S, Fini R, Fiorini M, Firlej M, Fischer K, Fitzpatrick C, Fiutowski T, Fleuret F, Fontana M, Fontanelli F, Forty R, Franco Lima V, Franco Sevilla M, Frank M, Franzoso E, Frau G, Frei C, Friday D, Fu J, Fuehring Q, Funk W, Gabriel E, Gaintseva T, Gallas Torreira A, Galli D, Gambetta S, Gan Y, Gandelman M, Gandini P, Gao Y, Garau M, Garcia Martin L, Garcia Moreno P, García Pardiñas J, Garcia Plana B, Garcia Rosales F, Garrido L, Gascon D, Gaspar C, Geertsema R, Gerick D, Gerken L, Gersabeck E, Gersabeck M, Gershon T, Gerstel D, Ghez P, Gibson V, Giovannetti M, Gioventù A, Gironella Gironell P, Giubega L, Giugliano C, Gizdov K, Gkougkousis E, Gligorov V, Göbel C, Golobardes E, Golubkov D, Golutvin A, Gomes A, Gomez Fernandez S, Goncalves Abrantes F, Goncerz M, Gong G, Gorbounov P, Gorelov I, Gotti C, Govorkova E, Grabowski J, Graciani Diaz R, Grammatico T, Granado Cardoso L, Graugés E, Graverini E, Graziani G, Grecu A, Greeven L, Griffith P, Grillo L, Gromov S, Gruber L, Gruberg Cazon B, Gu C, Guarise M, Günther P, Gushchin E, Guth A, Guz Y, Gys T, Hadavizadeh T, Haefeli G, Haen C, Haimberger J, Haines S, Halewood-leagas T, Hamilton P, Han Q, Han X, Hancock T, Hansmann-Menzemer S, Harnew N, Harrison T, Hasse C, Hatch M, He J, Hecker M, Heijhoff K, Heinicke K, Hennequin A, Hennessy K, Henry L, Heuel J, Hicheur A, Hill D, Hilton M, Hollitt S, Hopchev P, Hu J, Hu J, Hu W, Huang W, Huang X, Hulsbergen W, Hunter R, Hushchyn M, Hutchcroft D, Hynds D, Ibis P, Idzik M, Ilin D, Ilten P, Inglessi A, Ishteev A, Ivshin K, Jacobsson R, Jakobsen S, Jans E, Jashal B, Jawahery A, Jevtic V, Jezabek M, Jiang F, John M, Johnson D, Jones C, Jones T, Jost B, Jurik N, Kandybei S, Kang Y, Karacson M, Kariuki J, Kazeev N, Kecke M, Keizer F, Kenzie M, Ketel T, Khanji B, Kharisova A, Kholodenko S, Kim K, Kirn T, Kirsebom V, Kitouni O, Klaver S, Klimaszewski K, Koliiev S, Kondybayeva A, Konoplyannikov A, Kopciewicz P, Kopecna R, Koppenburg P, Korolev M, Kostiuk I, Kot O, Kotriakhova S, Kravchenko P, Kravchuk L, Krawczyk R, Kreps M, Kress F, Kretzschmar S, Krokovny P, Krupa W, Krzemien W, Kucewicz W, Kucharczyk M, Kudryavtsev V, Kuindersma H, Kunde G, Kvaratskheliya T, Lacarrere D, Lafferty G, Lai A, Lampis A, Lancierini D, Lane J, Lane R, Lanfranchi G, Langenbruch C, Langer J, Lantwin O, Latham T, Lazzari F, Le Gac R, Lee S, Lefèvre R, Leflat A, Legotin S, Leroy O, Lesiak T, Leverington B, Li H, Li L, Li P, Li X, Li Y, Li Y, Li Z, Liang X, Lin T, Lindner R, Lisovskyi V, Litvinov R, Liu G, Liu H, Liu S, Liu X, Loi A, Lomba Castro J, Longstaff I, Lopes J, Loustau G, Lovell G, Lu Y, Lucchesi D, Luchuk S, Lucio Martinez M, Lukashenko V, Luo Y, Lupato A, Luppi E, Lupton O, Lusiani A, Lyu X, Ma L, Maccolini S, Machefert F, Maciuc F, Macko V, Mackowiak P, Maddrell-Mander S, Madejczyk O, Madhan Mohan L, Maev O, Maevskiy A, Maisuzenko D, Majewski M, Malde S, Malecki B, Malinin A, Maltsev T, Malygina H, Manca G, Mancinelli G, Manera Escalero R, Manuzzi D, Marangotto D, Maratas J, Marchand J, Marconi U, Mariani S, Marin Benito C, Marinangeli M, Marino P, Marks J, Marshall P, Martellotti G, Martinazzoli L, Martinelli M, Martinez Santos D, Martinez Vidal F, Massafferri A, Materok M, Matev R, Mathad A, Mathe Z, Matiunin V, Matteuzzi C, Mattioli K, Mauri A, Maurice E, Mauricio J, Mazurek M, McCann M, Mcconnell L, Mcgrath T, McNab A, McNulty R, Mead J, Meadows B, Meaux C, Meier G, Meinert N, Melnychuk D, Meloni S, Merk M, Merli A, Meyer Garcia L, Mikhasenko M, Milanes D, Millard E, Milovanovic M, Minard MN, Minzoni L, Mitchell S, Mitreska B, Mitzel D, Mödden A, Mohammed R, Moise R, Mombächer T, Monroy I, Monteil S, Morandin M, Morello G, Morello M, Moron J, Morris A, Morris A, Mountain R, Mu H, Muheim F, Mukherjee M, Mulder M, Müller D, Müller K, Murphy C, Murray D, Muzzetto P, Naik P, Nakada T, Nandakumar R, Nanut T, Nasteva I, Needham M, Neri I, Neri N, Neubert S, Neufeld N, Newcombe R, Nguyen T, Nguyen-Mau C, Niel E, Nieswand S, Nikitin N, Nolte N, Nunez C, Oblakowska-Mucha A, Obraztsov V, O’Hanlon D, Oldeman R, Onderwater C, Ossowska A, Otalora Goicochea J, Ovsiannikova T, Owen P, Oyanguren A, Pagare B, Pais P, Pajero T, Palano A, Palutan M, Pan Y, Panshin G, Papanestis A, Pappagallo M, Pappalardo L, Pappenheimer C, Parker W, Parkes C, Parkinson C, Passalacqua B, Passaleva G, Pastore A, Patel M, Patrignani C, Pawley C, Pearce A, Pellegrino A, Pepe Altarelli M, Perazzini S, Pereima D, Perret P, Petridis K, Petrolini A, Petrov A, Petrucci S, Petruzzo M, Philippov A, Pica L, Piccini M, Pietrzyk B, Pietrzyk G, Pili M, Pinci D, Pinzino J, Pisani F, Piucci A, P. K R, Placinta V, Playfer S, Plews J, Plo Casasus M, Polci F, Poli Lener M, Poliakova M, Poluektov A, Polukhina N, Polyakov I, Polycarpo E, Pomery G, Ponce S, Popov A, Popov D, Popov S, Poslavskii S, Prasanth K, Promberger L, Prouve C, Pugatch V, Puig Navarro A, Pullen H, Punzi G, Qian W, Qin J, Quagliani R, Quintana B, Raab N, Rabadan Trejo R, Rachwal B, Rademacker J, Rama M, Ramos Pernas M, Rangel M, Ratnikov F, Raven G, Reboud M, Redi F, Reiss F, Remon Alepuz C, Ren Z, Renaudin V, Ribatti R, Ricciardi S, Richards D, Rinnert K, Robbe P, Robert A, Robertson G, Rodrigues A, Rodrigues E, Rodriguez Lopez J, Rollings A, Roloff P, Romanovskiy V, Romero Lamas M, Romero Vidal A, Roth J, Rotondo M, Rudolph M, Ruf T, Ruiz Vidal J, Ryzhikov A, Ryzka J, Saborido Silva J, Sagidova N, Sahoo N, Saitta B, Sanchez Gonzalo D, Sanchez Gras C, Sanchez Mayordomo C, Santacesaria R, Santamarina Rios C, Santimaria M, Santovetti E, Saranin D, Sarpis G, Sarpis M, Sarti A, Satriano C, Satta A, Saur M, Savrina D, Sazak H, Scantlebury Smead L, Schael S, Schellenberg M, Schiller M, Schindler H, Schmelling M, Schmelzer T, Schmidt B, Schneider O, Schopper A, Schubiger M, Schulte S, Schune M, Schwemmer R, Sciascia B, Sciubba A, Sellam S, Semennikov A, Senghi Soares M, Sergi A, Serra N, Serrano J, Sestini L, Seuthe A, Seyfert P, Shangase D, Shapkin M, Shchemerov I, Shchutska L, Shears T, Shekhtman L, Shen Z, Shevchenko V, Shields E, Shmanin E, Shupperd J, Siddi B, Silva Coutinho R, Simi G, Simone S, Skiba I, Skidmore N, Skwarnicki T, Slater M, Smallwood J, Smeaton J, Smetkina A, Smith E, Smith M, Snoch A, Soares M, Soares Lavra L, Sokoloff M, Soler F, Solovev A, Solovyev I, Souza De Almeida F, Souza De Paula B, Spaan B, Spadaro Norella E, Spradlin P, Stagni F, Stahl M, Stahl S, Stefko P, Steinkamp O, Stemmle S, Stenyakin O, Stevens H, Stone S, Stramaglia M, Straticiuc M, Strekalina D, Strokov S, Suljik F, Sun J, Sun L, Sun Y, Svihra P, Swallow P, Swientek K, Szabelski A, Szumlak T, Szymanski M, Taneja S, Tang Z, Tekampe T, Teubert F, Thomas E, Thomson K, Tilley M, Tisserand V, T’Jampens S, Tobin M, Tolk S, Tomassetti L, Torres Machado D, Tou D, Traill M, Tran M, Trifonova E, Trippl C, Tsaregorodtsev A, Tuci G, Tully A, Tuning N, Ukleja A, Unverzagt D, Usachov A, Ustyuzhanin A, Uwer U, Vagner A, Vagnoni V, Valassi A, Valenti G, Valls Canudas N, van Beuzekom M, Van Hecke H, van Herwijnen E, Van Hulse C, van Veghel M, Vazquez Gomez R, Vazquez Regueiro P, Vázquez Sierra C, Vecchi S, Velthuis J, Veltri M, Venkateswaran A, Veronesi M, Vesterinen M, Vieira D, Vieites Diaz M, Viemann H, Vilasis-Cardona X, Vilella Figueras E, Vincent P, Vitali G, Vollhardt A, Vom Bruch D, Vorobyev A, Vorobyev V, Voropaev N, Waldi R, Walsh J, Wang C, Wang J, Wang J, Wang J, Wang J, Wang M, Wang R, Wang Y, Wang Z, Ward D, Wark H, Watson N, Weber S, Websdale D, Weisser C, Westhenry B, White D, Whitehead M, Wiedner D, Wilkinson G, Wilkinson M, Williams I, Williams M, Williams M, Wilson F, Wislicki W, Witek M, Witola L, Wormser G, Wotton S, Wu H, Wyllie K, Xiang Z, Xiao D, Xie Y, Xing H, Xu A, Xu J, Xu L, Xu M, Xu Q, Xu Z, Xu Z, Yang D, Yang Y, Yang Z, Yang Z, Yao Y, Yeomans L, Yin H, Yu J, Yuan X, Yushchenko O, Zarebski K, Zavertyaev M, Zdybal M, Zenaiev O, Zeng M, Zhang D, Zhang L, Zhang S, Zhang Y, Zhang Y, Zhelezov A, Zheng Y, Zhou X, Zhou Y, Zhu X, Zhukov V, Zonneveld J, Zucchelli S, Zuliani D, Zunica G. Amplitude analysis of the
B+→D+D−K+
decay. Int J Clin Exp Med 2020. [DOI: 10.1103/physrevd.102.112003] [Show More Authors] [Citation(s) in RCA: 53] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
|
5 |
53 |
17
|
Aaij R, Abellán Beteta C, Adeva B, Adinolfi M, Aidala CA, Ajaltouni Z, Akar S, Albicocco P, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Alkhazov G, Alvarez Cartelle P, Alves AA, Amato S, Amhis Y, An L, Anderlini L, Andreassi G, Andreotti M, Andrews JE, Archilli F, d'Argent P, Arnau Romeu J, Artamonov A, Artuso M, Arzymatov K, Aslanides E, Atzeni M, Audurier B, Bachmann S, Back JJ, Baker S, Balagura V, Baldini W, Baranov A, Barlow RJ, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Batozskaya V, Batsukh B, Battig A, Battista V, Bay A, Bedeschi F, Bediaga I, Beiter A, Bel LJ, Belavin V, Belin S, Beliy N, Bellee V, Belloli N, Belous K, Belyaev I, Ben-Haim E, Bencivenni G, Benson S, Beranek S, Berezhnoy A, Bernet R, Berninghoff D, Bertholet E, Bertolin A, Betancourt C, Betti F, Bettler MO, van Beuzekom M, Bezshyiko I, Bhasin S, Bhom J, Bieker MS, Bifani S, Billoir P, Birnkraut A, Bizzeti A, Bjørn M, Blago MP, Blake T, Blanc F, Blusk S, Bobulska D, Bocci V, Boente Garcia O, Boettcher T, Bondar A, Bondar N, Borghi S, Borisyak M, Borsato M, Boubdir M, Bowcock TJV, Bozzi C, Braun S, Brea Rodriguez A, Brodski M, Brodzicka J, et alAaij R, Abellán Beteta C, Adeva B, Adinolfi M, Aidala CA, Ajaltouni Z, Akar S, Albicocco P, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Alkhazov G, Alvarez Cartelle P, Alves AA, Amato S, Amhis Y, An L, Anderlini L, Andreassi G, Andreotti M, Andrews JE, Archilli F, d'Argent P, Arnau Romeu J, Artamonov A, Artuso M, Arzymatov K, Aslanides E, Atzeni M, Audurier B, Bachmann S, Back JJ, Baker S, Balagura V, Baldini W, Baranov A, Barlow RJ, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Batozskaya V, Batsukh B, Battig A, Battista V, Bay A, Bedeschi F, Bediaga I, Beiter A, Bel LJ, Belavin V, Belin S, Beliy N, Bellee V, Belloli N, Belous K, Belyaev I, Ben-Haim E, Bencivenni G, Benson S, Beranek S, Berezhnoy A, Bernet R, Berninghoff D, Bertholet E, Bertolin A, Betancourt C, Betti F, Bettler MO, van Beuzekom M, Bezshyiko I, Bhasin S, Bhom J, Bieker MS, Bifani S, Billoir P, Birnkraut A, Bizzeti A, Bjørn M, Blago MP, Blake T, Blanc F, Blusk S, Bobulska D, Bocci V, Boente Garcia O, Boettcher T, Bondar A, Bondar N, Borghi S, Borisyak M, Borsato M, Boubdir M, Bowcock TJV, Bozzi C, Braun S, Brea Rodriguez A, Brodski M, Brodzicka J, Brossa Gonzalo A, Brundu D, Buchanan E, Buonaura A, Burr C, Bursche A, Butter JS, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Cali S, Calladine R, Calvi M, Calvo Gomez M, Camboni A, Campana P, Campora Perez DH, Capriotti L, Carbone A, Carboni G, Cardinale R, Cardini A, Carniti P, Carvalho Akiba K, Casais Vidal A, Casse G, Cattaneo M, Cavallero G, Cenci R, Chapman MG, Charles M, Charpentier P, Chatzikonstantinidis G, Chefdeville M, Chekalina V, Chen C, Chen S, Chitic SG, Chobanova V, Chrzaszcz M, Chubykin A, Ciambrone P, Cid Vidal X, Ciezarek G, Cindolo F, Clarke PEL, Clemencic M, Cliff HV, Closier J, Coco V, Coelho JAB, Cogan J, Cogneras E, Cojocariu L, Collins P, Colombo T, Comerma-Montells A, Contu A, Coombs G, Coquereau S, Corti G, Costa Sobral CM, Couturier B, Cowan GA, Craik DC, Crocombe A, Cruz Torres M, Currie R, D'Ambrosio C, Da Silva CL, Dall'Occo E, Dalseno J, Danilina A, Davis A, De Aguiar Francisco O, De Bruyn K, De Capua S, De Cian M, De Miranda JM, De Paula L, De Serio M, De Simone P, Dean CT, Dean W, Decamp D, Del Buono L, Delaney B, Dembinski HP, Demmer M, Dendek A, Derkach D, Deschamps O, Desse F, Dettori F, Dey B, Di Canto A, Di Nezza P, Didenko S, Dijkstra H, Dordei F, Dorigo M, Dosil Suárez A, Douglas L, Dovbnya A, Dreimanis K, Dufour L, Dujany G, Durante P, Durham JM, Dutta D, Dzhelyadin R, Dziewiecki M, Dziurda A, Dzyuba A, Easo S, Egede U, Egorychev V, Eidelman S, Eisenhardt S, Eitschberger U, Ek-In S, Ekelhof R, Eklund L, Ely S, Ene A, Escher S, Esen S, Evans T, Falabella A, Farley N, Farry S, Fazzini D, Fernandez Declara P, Fernandez Prieto A, Fernández-Ramírez C, Ferrari F, Ferreira Lopes L, Ferreira Rodrigues F, Ferreres Sole S, Ferro-Luzzi M, Filippov S, Fini RA, Fiorini M, Firlej M, Fitzpatrick C, Fiutowski T, Fleuret F, Fontana M, Fontanelli F, Forty R, Franco Lima V, Franco Sevilla M, Frank M, Frei C, Fu J, Funk W, Färber C, Féo M, Gabriel E, Gallas Torreira A, Galli D, Gallorini S, Gambetta S, Gan Y, Gandelman M, Gandini P, Gao Y, Garcia Martin LM, Garcia Plana B, García Pardiñas J, Garra Tico J, Garrido L, Gascon D, Gaspar C, Gazzoni G, Gerick D, Gersabeck E, Gersabeck M, Gershon T, Gerstel D, Ghez P, Gibson V, Girard OG, Gironella Gironell P, Giubega L, Gizdov K, Gligorov VV, Golubkov D, Golutvin A, Gomes A, Gorelov IV, Gotti C, Govorkova E, Grabowski JP, Graciani Diaz R, Granado Cardoso LA, Graugés E, Graverini E, Graziani G, Grecu A, Greim R, Griffith P, Grillo L, Gruber L, Gruberg Cazon BR, Gu C, Guo X, Gushchin E, Guth A, Guz Y, Gys T, Göbel C, Hadavizadeh T, Hadjivasiliou C, Haefeli G, Haen C, Haines SC, Hamilton B, Han Q, Han X, Hancock TH, Hansmann-Menzemer S, Harnew N, Harrison T, Hasse C, Hatch M, He J, Hecker M, Heinicke K, Heister A, Hennessy K, Henry L, van Herwijnen E, Heuel J, Heß M, Hicheur A, Hidalgo Charman R, Hill D, Hilton M, Hopchev PH, Hu J, Hu W, Huang W, Huard ZC, Hulsbergen W, Humair T, Hushchyn M, Hutchcroft D, Hynds D, Ibis P, Idzik M, Ilten P, Inglessi A, Inyakin A, Ivshin K, Jacobsson R, Jakobsen S, Jalocha J, Jans E, Jashal BK, Jawahery A, Jiang F, John M, Johnson D, Jones CR, Joram C, Jost B, Jurik N, Kandybei S, Karacson M, Kariuki JM, Karodia S, Kazeev N, Kecke M, Keizer F, Kelsey M, Kenzie M, Ketel T, Khanji B, Kharisova A, Khurewathanakul C, Kim KE, Kirn T, Kirsebom VS, Klaver S, Klimaszewski K, Koliiev S, Kolpin M, Kondybayeva A, Konoplyannikov A, Kopecna R, Koppenburg P, Kostiuk I, Kot O, Kotriakhova S, Kozeiha M, Kravchuk L, Kreps M, Kress F, Kretzschmar S, Krokovny P, Krupa W, Krzemien W, Kucewicz W, Kucharczyk M, Kudryavtsev V, Kunde GJ, Kuonen AK, Kvaratskheliya T, Lacarrere D, Lafferty G, Lai A, Lancierini D, Lanfranchi G, Langenbruch C, Latham T, Lazzeroni C, Le Gac R, Leflat A, Lefèvre R, Lemaitre F, Leroy O, Lesiak T, Leverington B, Li H, Li PR, Li X, Li Y, Li Z, Liang X, Likhomanenko T, Lindner R, Ling P, Lionetto F, Lisovskyi V, Liu G, Liu X, Loh D, Loi A, Lomba Castro J, Longstaff I, Lopes JH, Loustau G, Lovell GH, Lucchesi D, Lucio Martinez M, Luo Y, Lupato A, Luppi E, Lupton O, Lusiani A, Lyu X, Ma R, Machefert F, Maciuc F, Macko V, Mackowiak P, Maddrell-Mander S, Maev O, Maguire K, Maisuzenko D, Majewski MW, Malde S, Malecki B, Malinin A, Maltsev T, Malygina H, Manca G, Mancinelli G, Marangotto D, Maratas J, Marchand JF, Marconi U, Marin Benito C, Marinangeli M, Marino P, Marks J, Marshall PJ, Martellotti G, Martinazzoli L, Martinelli M, Martinez Santos D, Martinez Vidal F, Massafferri A, Materok M, Matev R, Mathad A, Mathe Z, Matiunin V, Matteuzzi C, Mattioli KR, Mauri A, Maurice E, Maurin B, McCann M, McNab A, McNulty R, Mead JV, Meadows B, Meaux C, Meinert N, Melnychuk D, Merk M, Merli A, Michielin E, Mikhasenko M, Milanes DA, Millard E, Minard MN, Minzoni L, Mitzel DS, Mogini A, Moise RD, Mombächer T, Monroy IA, Monteil S, Morandin M, Morello G, Morello MJ, Moron J, Morris AB, Mountain R, Mu H, Muheim F, Mukherjee M, Mulder M, Murphy CH, Murray D, Mödden A, Müller D, Müller J, Müller K, Müller V, Naik P, Nakada T, Nandakumar R, Nandi A, Nanut T, Nasteva I, Needham M, Neri N, Neubert S, Neufeld N, Newcombe R, Nguyen TD, Nguyen-Mau C, Nieswand S, Niet R, Nikitin N, Nolte NS, O'Hanlon DP, Oblakowska-Mucha A, Obraztsov V, Ogilvy S, Oldeman R, Onderwater CJG, Osborn JD, Ossowska A, Otalora Goicochea JM, Ovsiannikova T, Owen P, Oyanguren A, Pais PR, Pajero T, Palano A, Palutan M, Panshin G, Papanestis A, Pappagallo M, Pappalardo LL, Parker W, Parkes C, Passaleva G, Pastore A, Patel M, Patrignani C, Pearce A, Pellegrino A, Penso G, Pepe Altarelli M, Perazzini S, Pereima D, Perret P, Pescatore L, Petridis K, Petrolini A, Petrov A, Petrucci S, Petruzzo M, Pietrzyk B, Pietrzyk G, Pikies M, Pili M, Pilloni A, Pinci D, Pinzino J, Pisani F, Piucci A, Placinta V, Playfer S, Plews J, Plo Casasus M, Polci F, Poli Lener M, Poliakova M, Poluektov A, Polukhina N, Polyakov I, Polycarpo E, Pomery GJ, Ponce S, Popov A, Popov D, Poslavskii S, Price E, Prouve C, Pugatch V, Puig Navarro A, Pullen H, Punzi G, Qian W, Qin J, Quagliani R, Quintana B, Raab NV, Rachwal B, Rademacker JH, Rama M, Ramos Pernas M, Rangel MS, Ratnikov F, Raven G, Ravonel Salzgeber M, Reboud M, Redi F, Reichert S, Dos Reis AC, Reiss F, Remon Alepuz C, Ren Z, Renaudin V, Ricciardi S, Richards S, Rinnert K, Robbe P, Robert A, Rodrigues AB, Rodrigues E, Rodriguez Lopez JA, Roehrken M, Roiser S, Rollings A, Romanovskiy V, Romero Vidal A, Roth JD, Rotondo M, Rudolph MS, Ruf T, Ruiz Vidal J, Saborido Silva JJ, Sagidova N, Saitta B, Salustino Guimaraes V, Sanchez Gras C, Sanchez Mayordomo C, Sanmartin Sedes B, Santacesaria R, Santamarina Rios C, Santimaria M, Santovetti E, Sarpis G, Sarti A, Satriano C, Satta A, Saur M, Savrina D, Schael S, Schellenberg M, Schiller M, Schindler H, Schmelling M, Schmelzer T, Schmidt B, Schneider O, Schopper A, Schreiner HF, Schubiger M, Schulte S, Schune MH, Schwemmer R, Sciascia B, Sciubba A, Semennikov A, Sepulveda ES, Sergi A, Serra N, Serrano J, Sestini L, Seuthe A, Seyfert P, Shapkin M, Shears T, Shekhtman L, Shevchenko V, Shmanin E, Siddi BG, Silva Coutinho R, Silva de Oliveira L, Simi G, Simone S, Skiba I, Skidmore N, Skwarnicki T, Slater MW, Smeaton JG, Smith E, Smith IT, Smith M, Soares M, Soares Lavra L, Sokoloff MD, Soler FJP, Souza De Paula B, Spaan B, Spadaro Norella E, Spradlin P, Stagni F, Stahl M, Stahl S, Stefko P, Stefkova S, Steinkamp O, Stemmle S, Stenyakin O, Stepanova M, Stevens H, Stocchi A, Stone S, Stracka S, Stramaglia ME, Straticiuc M, Straumann U, Strokov S, Sun J, Sun L, Sun Y, Swientek K, Szabelski A, Szczepaniak A, Szumlak T, Szymanski M, T'Jampens S, Tang Z, Tekampe T, Tellarini G, Teubert F, Thomas E, van Tilburg J, Tilley MJ, Tisserand V, Tobin M, Tolk S, Tomassetti L, Tonelli D, Tou DY, Tournefier E, Traill M, Tran MT, Trisovic A, Tsaregorodtsev A, Tuci G, Tully A, Tuning N, Ukleja A, Usachov A, Ustyuzhanin A, Uwer U, Vagner A, Vagnoni V, Valassi A, Valat S, Valenti G, Van Hecke H, Van Hulse CB, Vasiliev A, Vazquez Gomez R, Vazquez Regueiro P, Vecchi S, van Veghel M, Velthuis JJ, Veltri M, Venkateswaran A, Vernet M, Veronesi M, Vesterinen M, Viana Barbosa JV, Vieira D, Vieites Diaz M, Viemann H, Vilasis-Cardona X, Vitkovskiy A, Vitti M, Volkov V, Vollhardt A, Vom Bruch D, Voneki B, Vorobyev A, Vorobyev V, Voropaev N, de Vries JA, Vázquez Sierra C, Waldi R, Walsh J, Wang J, Wang J, Wang M, Wang Y, Wang Z, Ward DR, Wark HM, Watson NK, Websdale D, Weiden A, Weisser C, Whitehead M, Wilkinson G, Wilkinson M, Williams I, Williams MRJ, Williams M, Williams T, Wilson FF, Winn M, Wislicki W, Witek M, Wormser G, Wotton SA, Wyllie K, Xiao D, Xie Y, Xing H, Xu A, Xu L, Xu M, Xu Q, Xu Z, Xu Z, Yang Z, Yang Z, Yao Y, Yeomans LE, Yin H, Yu J, Yuan X, Yushchenko O, Zarebski KA, Zavertyaev M, Zeng M, Zhang D, Zhang L, Zhang S, Zhang WC, Zhang Y, Zhelezov A, Zheng Y, Zhu X, Zhukov V, Zonneveld JB, Zucchelli S. Observation of a Narrow Pentaquark State, P_{c}(4312)^{+}, and of the Two-Peak Structure of the P_{c}(4450)^{+}. PHYSICAL REVIEW LETTERS 2019; 122:222001. [PMID: 31283265 DOI: 10.1103/physrevlett.122.222001] [Show More Authors] [Citation(s) in RCA: 52] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/06/2019] [Indexed: 06/09/2023]
Abstract
A narrow pentaquark state, P_{c}(4312)^{+}, decaying to J/ψp, is discovered with a statistical significance of 7.3σ in a data sample of Λ_{b}^{0}→J/ψpK^{-} decays, which is an order of magnitude larger than that previously analyzed by the LHCb Collaboration. The P_{c}(4450)^{+} pentaquark structure formerly reported by LHCb is confirmed and observed to consist of two narrow overlapping peaks, P_{c}(4440)^{+} and P_{c}(4457)^{+}, where the statistical significance of this two-peak interpretation is 5.4σ. The proximity of the Σ_{c}^{+}D[over ¯]^{0} and Σ_{c}^{+}D[over ¯]^{*0} thresholds to the observed narrow peaks suggests that they play an important role in the dynamics of these states.
Collapse
|
|
6 |
52 |
18
|
Magalhaes Moreira DR, Lima Leite A, Santos RR, Soares M. Approaches for the Development of New Anti-Trypanosoma cruzi Agents. Curr Drug Targets 2009; 10:212-31. [DOI: 10.2174/138945009787581140] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
|
16 |
52 |
19
|
Pereira S, Oliveira e Silva A, Quintas M, Almeida J, Marujo C, Pizarro M, Angélico V, Fonseca L, Loureiro E, Barroso S, Machado A, Soares M, da Costa AB, de Freitas AF. Appropriateness of emergency department visits in a Portuguese university hospital. Ann Emerg Med 2001; 37:580-6. [PMID: 11385326 DOI: 10.1067/mem.2001.114306] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
STUDY OBJECTIVE There are no studies in Portugal supporting a common claim that most emergency department visits are inappropriate. The aim of this study was to determine the prevalence of and to evaluate factors associated with an appropriate ED visit in a major public hospital. METHODS A cross-sectional prospective study was performed at a public university hospital ED. Data for demographic variables, duration of complaint, transfer from other medical sources, and previous medical care for the same complaints were collected by interviewing all patients who arrived at the ED within a consecutive period of at least 24 hours. Data for diagnostic tests, treatment performed, and final patient destination were collected by triage records review. An appropriate ED visit was defined by explicit criteria: interhospital transfer, patient death at the ED, hospitalization, and diagnostic tests or treatments performed. RESULTS The study included 5,818 adult patients. The prevalence of an appropriate ED visit, by use of our criteria, was 68.7%. Sex was an effect modifier. According to this study, determinants of an appropriate visit for men and women were age 60 years or older and complaints of 24 hours or less and in women but not in men, retired from work and with arrival between midnight and 8 AM. CONCLUSIONS In a university hospital in Oporto, the majority of ED visits were appropriate according to explicit criteria. Some variables may be associated with appropriateness of ED visits. A duration of the complaint 24 hours or less along with an arrival between midnight and 8 AM in women and age 60 years or older in men were the most important determinants.
Collapse
|
|
24 |
45 |
20
|
Soares M, Sahrari K, Chiti M, Amorim C, Ambroise J, Donnez J, Dolmans MM. The best source of isolated stromal cells for the artificial ovary: medulla or cortex, cryopreserved or fresh? Hum Reprod 2015; 30:1589-98. [DOI: 10.1093/humrep/dev101] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2015] [Accepted: 04/20/2015] [Indexed: 01/28/2023] Open
|
|
10 |
45 |
21
|
Bacani JT, Soares M, Zwingerman R, di Nicola N, Senz J, Riddell R, Huntsman DG, Gallinger S. CDH1/E-cadherin germline mutations in early-onset gastric cancer. J Med Genet 2006; 43:867-72. [PMID: 16801346 PMCID: PMC2563190 DOI: 10.1136/jmg.2006.043133] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND Gastric cancer remains a leading cause of cancer deaths worldwide. Genetic factors, including germline mutations in E-cadherin (CDH1, MIM#192090) in hereditary diffuse gastric cancer (HDGC, MIM#137215), are implicated in this disease. Family studies have reported CDH1 germline mutations in HDGC but the role of CDH1 germline mutations in the general population remains unclear. AIMS To examine the frequency of CDH1 germline mutations in a population-based series of early-onset gastric cancer (EOGC <50 years old). METHODS 211 cases of EOGC were identified in Central-East Ontario region from 1989 to 1993, with archival material and histological confirmation of non-intestinal type gastric cancer available for 81 subjects. Eligible cases were analysed for CDH1 germline mutations by single-strand conformation polymorphism, variants were sequenced, and tumours from cases with functional mutations were stained for E-cadherin (HECD-1) using immunohistochemistry. RESULTS 1155 (89%) of 1296 polymerase chain reactions amplified successfully. One new germline deletion (nt41delT) was identified in a 30-year-old patient with isolated cell gastric cancer. The overall frequency of germline CDH1 mutations was 1.3% (1/81) for EOGC and 2.8% (1/36) for early-onset isolated cell gastric cancer. CONCLUSION This is the first population-based study, in a low-incidence region, of genetic predisposition to gastric cancer. Combined with our previous report of germline hMLH1 mutations in two other subjects from this series, it is suggested that 2-3% of EOCG cases in North Americans may be owing to high-risk genetic mutations. These data should inform cancer geneticists on the utility of searching for specific genetic mutations in EOGC.
Collapse
|
Research Support, Non-U.S. Gov't |
19 |
35 |
22
|
Marteau T, Drake H, Reid M, Feijoo M, Soares M, Nippert I, Nippert P, Bobrow M. Counselling following diagnosis of fetal abnormality: a comparison between German, Portuguese and UK geneticists. Eur J Hum Genet 1994; 2:96-102. [PMID: 8044661 DOI: 10.1159/000472349] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
The principle of non-directiveness in genetic counselling is embraced by all relevant professional bodies. Little is known about the extent to which it is endorsed by geneticists, or incorporated into their clinical practice. The aim of the current study is to document how geneticists in three European countries, Germany, Portugal and the UK, report counselling women at risk for having children with a range of conditions. While geneticists in all three countries reported counselling in a largely non-directive style, this varied both across genetic conditions and between countries. German and Portuguese geneticists were significantly more directive than UK geneticists, although they differed in the way in which they were directive. German geneticists were more likely to encourage continuation of pregnancies, while Portuguese geneticists were more likely to encourage termination of affected pregnancies. There was no strong consensus on approaches to counselling for any of the genetic conditions, defined as agreement between 70% of all three groups of geneticists. Despite strong professional codes of non-directiveness, geneticists report being somewhat directive in some counselling situations. Future research needs to focus on what geneticists are trying to achieve in genetic counselling, how they actually counsel, and with what effects.
Collapse
|
Comparative Study |
31 |
35 |
23
|
Souza-Dantas V, Salluh J, Soares M. Impact of neutropenia on the outcomes of critically ill patients with cancer: a matched case–control study. Ann Oncol 2011; 22:2094-2100. [DOI: 10.1093/annonc/mdq711] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
|
|
14 |
33 |
24
|
Castro V, Origa AF, Annichino-Bizzacchi JM, Soares M, Menezes RC, Gonçalves MS, Costa FF, Arruda VR. Frequencies of platelet-specific alloantigen systems 1-5 in three distinct ethnic groups in Brazil. EUROPEAN JOURNAL OF IMMUNOGENETICS : OFFICIAL JOURNAL OF THE BRITISH SOCIETY FOR HISTOCOMPATIBILITY AND IMMUNOGENETICS 1999; 26:355-60. [PMID: 10553502 DOI: 10.1046/j.1365-2370.1999.00174.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The human platelet antigen (HPA) systems are related to immune platelet disorders as well as to the development of occlusive vascular disease. Several distinct biallelic HPA systems are known, and a heterogeneous distribution of HPA alleles has been described among distinct ethnic groups. In this study we genotyped 320 carefully selected individuals from three distinct ethnic groups in Brazil (Caucasians, Blacks and Amazonian Indians) for the HPA-1, -2, -3, -4 and -5 systems. A similar prevalence for all HPA alleles was found in Brazilians of Caucasian and Black descent. These data contrast with those reported for similar ethnic groups in other countries. Among the Amazonian Indians, no b allele of the HPA-1, -4 and -5 systems was identified. The data presented here could be useful in the diagnosis of alloimmune platelet disease, in genetic counselling and in the development of screening programmes for HPA-related diseases.
Collapse
|
|
26 |
32 |
25
|
Aaij R, Abellán Beteta C, Adeva B, Adinolfi M, Aidala C, Ajaltouni Z, Akar S, Albicocco P, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Alkhazov G, Alvarez Cartelle P, Alves A, Amato S, Amerio S, Amhis Y, An L, Anderlini L, Andreassi G, Andreotti M, Andrews J, Archilli F, Arnau Romeu J, Artamonov A, Artuso M, Arzymatov K, Aslanides E, Atzeni M, Audurier B, Bachmann S, Back J, Baker S, Balagura V, Baldini W, Baranov A, Barlow R, Barrand G, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Batozskaya V, Batsukh B, Battig A, Battista V, Bay A, Beddow J, Bedeschi F, Bediaga I, Beiter A, Bel L, Belin S, Beliy N, Bellee V, Belloli N, Belous K, Belyaev I, Bencivenni G, Ben-Haim E, Benson S, Beranek S, Berezhnoy A, Bernet R, Berninghoff D, Bertholet E, Bertolin A, Betancourt C, Betti F, Bettler M, Bezshyiko I, Bhasin S, Bhom J, Bieker M, Bifani S, Billoir P, Birnkraut A, Bizzeti A, Bjørn M, Blago M, Blake T, Blanc F, Blusk S, Bobulska D, Bocci V, Boente Garcia O, Boettcher T, Bondar A, Bondar N, Borghi S, Borisyak M, Borsato M, Boubdir M, Bowcock T, Bozzi C, Braun S, Brodski M, Brodzicka J, Brossa Gonzalo A, et alAaij R, Abellán Beteta C, Adeva B, Adinolfi M, Aidala C, Ajaltouni Z, Akar S, Albicocco P, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Alkhazov G, Alvarez Cartelle P, Alves A, Amato S, Amerio S, Amhis Y, An L, Anderlini L, Andreassi G, Andreotti M, Andrews J, Archilli F, Arnau Romeu J, Artamonov A, Artuso M, Arzymatov K, Aslanides E, Atzeni M, Audurier B, Bachmann S, Back J, Baker S, Balagura V, Baldini W, Baranov A, Barlow R, Barrand G, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Batozskaya V, Batsukh B, Battig A, Battista V, Bay A, Beddow J, Bedeschi F, Bediaga I, Beiter A, Bel L, Belin S, Beliy N, Bellee V, Belloli N, Belous K, Belyaev I, Bencivenni G, Ben-Haim E, Benson S, Beranek S, Berezhnoy A, Bernet R, Berninghoff D, Bertholet E, Bertolin A, Betancourt C, Betti F, Bettler M, Bezshyiko I, Bhasin S, Bhom J, Bieker M, Bifani S, Billoir P, Birnkraut A, Bizzeti A, Bjørn M, Blago M, Blake T, Blanc F, Blusk S, Bobulska D, Bocci V, Boente Garcia O, Boettcher T, Bondar A, Bondar N, Borghi S, Borisyak M, Borsato M, Boubdir M, Bowcock T, Bozzi C, Braun S, Brodski M, Brodzicka J, Brossa Gonzalo A, Brundu D, Buchanan E, Buonaura A, Burr C, Bursche A, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Calladine R, Calvi M, Calvo Gomez M, Camboni A, Campana P, Campora Perez D, Capriotti L, Carbone A, Carboni G, Cardinale R, Cardini A, Carniti P, Carvalho Akiba K, Casse G, Cattaneo M, Cavallero G, Cenci R, Chamont D, Chapman M, Charles M, Charpentier P, Chatzikonstantinidis G, Chefdeville M, Chekalina V, Chen C, Chen S, Chitic SG, Chobanova V, Chrzaszcz M, Chubykin A, Ciambrone P, Cid Vidal X, Ciezarek G, Cindolo F, Clarke P, Clemencic M, Cliff H, Closier J, Coco V, Coelho J, Cogan J, Cogneras E, Cojocariu L, Collins P, Colombo T, Comerma-Montells A, Contu A, Coombs G, Coquereau S, Corti G, Corvo M, Costa Sobral C, Couturier B, Cowan G, Craik D, Crocombe A, Cruz Torres M, Currie R, Da Cunha Marinho F, Da Silva C, Dall’Occo E, Dalseno J, D’Ambrosio C, Danilina A, d’Argent P, Davis A, De Aguiar Francisco O, De Bruyn K, De Capua S, De Cian M, De Miranda J, De Paula L, De Serio M, De Simone P, de Vries J, Dean C, Dean W, Decamp D, Del Buono L, Delaney B, Dembinski HP, Demmer M, Dendek A, Derkach D, Deschamps O, Desse F, Dettori F, Dey B, Di Canto A, Di Nezza P, Didenko S, Dijkstra H, Dordei F, Dorigo M, dos Reis A, Dosil Suárez A, Douglas L, Dovbnya A, Dreimanis K, Dufour L, Dujany G, Durante P, Durham J, Dutta D, Dzhelyadin R, Dziewiecki M, Dziurda A, Dzyuba A, Easo S, Egede U, Egorychev V, Eidelman S, Eisenhardt S, Eitschberger U, Ekelhof R, Eklund L, Ely S, Ene A, Escher S, Esen S, Evans T, Falabella A, Färber C, Farley N, Farry S, Fazzini D, Féo M, Fernandez Declara P, Fernandez Prieto A, Ferrari F, Ferreira Lopes L, Ferreira Rodrigues F, Ferro-Luzzi M, Filippov S, Fini R, Fiorini M, Firlej M, Fitzpatrick C, Fiutowski T, Fleuret F, Fontana M, Fontanelli F, Forty R, Franco Lima V, Frank M, Frei C, Fu J, Funk W, Gabriel E, Gallas Torreira A, Galli D, Gallorini S, Gambetta S, Gan Y, Gandelman M, Gandini P, Gao Y, Garcia Martin L, García Pardiñas J, Garcia Plana B, Garra Tico J, Garrido L, Gascon D, Gaspar C, Gazzoni G, Gerick D, Gersabeck E, Gersabeck M, Gershon T, Gerstel D, Ghez P, Gibson V, Girard O, Gironella Gironell P, Giubega L, Gizdov K, Gligorov V, Göbel C, Golubkov D, Golutvin A, Gomes A, Gorelov I, Gotti C, Govorkova E, Grabowski J, Graciani Diaz R, Granado Cardoso L, Graugés E, Graverini E, Graziani G, Grecu A, Greim R, Griffith P, Grillo L, Gruber L, Gruberg Cazon B, Grünberg O, Gu C, Gushchin E, Guth A, Guz Y, Gys T, Hadavizadeh T, Hadjivasiliou C, Haefeli G, Haen C, Haines S, Hamilton B, Han X, Hancock T, Hansmann-Menzemer S, Harnew N, Harrison T, Hasse C, Hatch M, He J, Hecker M, Heinicke K, Heister A, Hennessy K, Henry L, Heß M, Heuel J, Hicheur A, Hidalgo Charman R, Hill D, Hilton M, Hopchev P, Hu J, Hu W, Huang W, Huard Z, Hulsbergen W, Humair T, Hushchyn M, Hutchcroft D, Hynds D, Ibis P, Idzik M, Ilten P, Inglessi A, Inyakin A, Ivshin K, Jacobsson R, Jakobsen S, Jalocha J, Jans E, Jashal B, Jawahery A, Jiang F, John M, Johnson D, Jones C, Joram C, Jost B, Jurik N, Kandybei S, Karacson M, Kariuki J, Karodia S, Kazeev N, Kecke M, Keizer F, Kelsey M, Kenzie M, Ketel T, Khairullin E, Khanji B, Khurewathanakul C, Kim K, Kirn T, Kirsebom V, Klaver S, Klimaszewski K, Klimkovich T, Koliiev S, Kolpin M, Kopecna R, Koppenburg P, Kostiuk I, Kotriakhova S, Kozeiha M, Kravchuk L, Kreps M, Kress F, Krokovny P, Krupa W, Krzemien W, Kucewicz W, Kucharczyk M, Kudryavtsev V, Kuonen A, Kvaratskheliya T, Lacarrere D, Lafferty G, Lai A, Lancierini D, Lanfranchi G, Langenbruch C, Latham T, Lazzeroni C, Le Gac R, Lefèvre R, Leflat A, Lemaitre F, Leroy O, Lesiak T, Leverington B, Li PR, Li Y, Li Z, Liang X, Likhomanenko T, Lindner R, Lionetto F, Lisovskyi V, Liu G, Liu X, Loh D, Loi A, Longstaff I, Lopes J, Loustau G, Lovell G, Lucchesi D, Lucio Martinez M, Luo Y, Lupato A, Luppi E, Lupton O, Lusiani A, Lyu X, Machefert F, Maciuc F, Macko V, Mackowiak P, Maddrell-Mander S, Maev O, Maguire K, Maisuzenko D, Majewski M, Malde S, Malecki B, Malinin A, Maltsev T, Malygina H, Manca G, Mancinelli G, Marangotto D, Maratas J, Marchand J, Marconi U, Marin Benito C, Marinangeli M, Marino P, Marks J, Marshall P, Martellotti G, Martinelli M, Martinez Santos D, Martinez Vidal F, Massafferri A, Materok M, Matev R, Mathad A, Mathe Z, Matteuzzi C, Mattioli K, Mauri A, Maurice E, Maurin B, McCann M, McNab A, McNulty R, Mead J, Meadows B, Meaux C, Meinert N, Melnychuk D, Merk M, Merli A, Michielin E, Milanes D, Millard E, Minard MN, Minzoni L, Mitzel D, Mödden A, Mogini A, Moise R, Mombächer T, Monroy I, Monteil S, Morandin M, Morello G, Morello M, Morgunova O, Moron J, Morris A, Mountain R, Muheim F, Mukherjee M, Mulder M, Müller D, Müller J, Müller K, Müller V, Murphy C, Murray D, Naik P, Nakada T, Nandakumar R, Nandi A, Nanut T, Nasteva I, Needham M, Neri N, Neubert S, Neufeld N, Newcombe R, Nguyen T, Nguyen-Mau C, Nieswand S, Niet R, Nikitin N, Nogay A, Nolte N, Oblakowska-Mucha A, Obraztsov V, Ogilvy S, O’Hanlon D, Oldeman R, Onderwater C, Ossowska A, Otalora Goicochea J, Ovsiannikova T, Owen P, Oyanguren A, Pais P, Pajero T, Palano A, Palutan M, Panshin G, Papanestis A, Pappagallo M, Pappalardo L, Parker W, Parkes C, Passaleva G, Pastore A, Patel M, Patrignani C, Pearce A, Pellegrino A, Penso G, Pepe Altarelli M, Perazzini S, Pereima D, Perret P, Pescatore L, Petridis K, Petrolini A, Petrov A, Petrucci S, Petruzzo M, Pietrzyk B, Pietrzyk G, Pikies M, Pili M, Pinci D, Pinzino J, Pisani F, Piucci A, Placinta V, Playfer S, Plews J, Plo Casasus M, Polci F, Poli Lener M, Poluektov A, Polukhina N, Polyakov I, Polycarpo E, Pomery G, Ponce S, Popov A, Popov D, Poslavskii S, Price E, Prisciandaro J, Prouve C, Pugatch V, Puig Navarro A, Pullen H, Punzi G, Qian W, Qin J, Quagliani R, Quintana B, Raab N, Rachwal B, Rademacker J, Rama M, Ramos Pernas M, Rangel M, Ratnikov F, Raven G, Ravonel Salzgeber M, Reboud M, Redi F, Reichert S, Reiss F, Remon Alepuz C, Ren Z, Renaudin V, Ricciardi S, Richards S, Rinnert K, Robbe P, Robert A, Rodrigues A, Rodrigues E, Rodriguez Lopez J, Roehrken M, Roiser S, Rollings A, Romanovskiy V, Romero Vidal A, Roth J, Rotondo M, Rudolph M, Ruf T, Ruiz Vidal J, Saborido Silva J, Sagidova N, Saitta B, Salustino Guimaraes V, Sanchez Gras C, Sanchez Mayordomo C, Sanmartin Sedes B, Santacesaria R, Santamarina Rios C, Santimaria M, Santovetti E, Sarpis G, Sarti A, Satriano C, Satta A, Saur M, Savrina D, Schael S, Schellenberg M, Schiller M, Schindler H, Schmelling M, Schmelzer T, Schmidt B, Schneider O, Schopper A, Schreiner H, Schubiger M, Schulte S, Schune M, Schwemmer R, Sciascia B, Sciubba A, Semennikov A, Sepulveda E, Sergi A, Serra N, Serrano J, Sestini L, Seuthe A, Seyfert P, Shapkin M, Shears T, Shekhtman L, Shevchenko V, Shmanin E, Siddi B, Silva Coutinho R, Silva de Oliveira L, Simi G, Simone S, Skiba I, Skidmore N, Skwarnicki T, Slater M, Smeaton J, Smith E, Smith I, Smith M, Soares M, Soares Lavra L, Sokoloff M, Soler F, Souza De Paula B, Spaan B, Spadaro Norella E, Spradlin P, Stagni F, Stahl M, Stahl S, Stefko P, Stefkova S, Steinkamp O, Stemmle S, Stenyakin O, Stepanova M, Stevens H, Stocchi A, Stone S, Storaci B, Stracka S, Stramaglia M, Straticiuc M, Straumann U, Strokov S, Sun J, Sun L, Sun Y, Swientek K, Szabelski A, Szumlak T, Szymanski M, Tang Z, Tekampe T, Tellarini G, Teubert F, Thomas E, Tilley M, Tisserand V, T’Jampens S, Tobin M, Tolk S, Tomassetti L, Tonelli D, Tou D, Tourinho Jadallah Aoude R, Tournefier E, Traill M, Tran M, Trisovic A, Tsaregorodtsev A, Tuci G, Tully A, Tuning N, Ukleja A, Usachov A, Ustyuzhanin A, Uwer U, Vagner A, Vagnoni V, Valassi A, Valat S, Valenti G, van Beuzekom M, van Herwijnen E, van Tilburg J, van Veghel M, Vazquez Gomez R, Vazquez Regueiro P, Vázquez Sierra C, Vecchi S, Velthuis J, Veltri M, Venkateswaran A, Vernet M, Veronesi M, Vesterinen M, Viana Barbosa J, Vieira D, Vieites Diaz M, Viemann H, Vilasis-Cardona X, Vitkovskiy A, Vitti M, Volkov V, Vollhardt A, Vom Bruch D, Voneki B, Vorobyev A, Vorobyev V, Voropaev N, Waldi R, Walsh J, Wang J, Wang M, Wang Y, Wang Z, Ward D, Wark H, Watson N, Websdale D, Weiden A, Weisser C, Whitehead M, Wilkinson G, Wilkinson M, Williams I, Williams M, Williams M, Williams T, Wilson F, Winn M, Wislicki W, Witek M, Wormser G, Wotton S, Wyllie K, Xiao D, Xie Y, Xu A, Xu M, Xu Q, Xu Z, Xu Z, Yang Z, Yang Z, Yao Y, Yeomans L, Yin H, Yu J, Yuan X, Yushchenko O, Zarebski K, Zavertyaev M, Zhang D, Zhang L, Zhang W, Zhang Y, Zhelezov A, Zheng Y, Zhu X, Zhukov V, Zonneveld J, Zucchelli S. Measurement of
b
hadron fractions in 13 TeV
pp
collisions. Int J Clin Exp Med 2019. [DOI: 10.1103/physrevd.100.031102] [Show More Authors] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
|
6 |
31 |